<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        28-249-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FENTANYL Transdermal System 50 mcg/h
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FENTANYL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Transdermal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Transdermal patch
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Box
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        166.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AVEVA Drug Delivery Systems " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AVEVA Drug Delivery Systems 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N02AB03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Remember, this information does not take the place of your doctor&#39;s instructions.</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><ul><li>Keep FENTANYL TRANSDERMAL SYSTEM in a safe place away from children and pets. Accidental use by a child or pet is a medical emergency and may result in death. If a child or pet accidentally uses FENTANYL TRANSDERMAL SYSTEM, get emergency help right away.</li><li>Do not use the FENTANYL TRANSDERMAL SYSTEM patch if the seal is broken or the patch is cut, damaged or changed in any way.</li><li>Make sure you read the section, HOW TO USE THIS MEDICATION. Follow the instructions and always use a FENTANYL TRANSDERMAL SYSTEM patch the right way. FENTANYL TRANSDERMAL SYSTEM can cause serious breathing problems and death, especially if it is used the wrong way.</li><li>Tell your doctor if you (or a family member) have ever abused or been dependent on alcohol, prescription medicines or street drugs.</li></ul></td></tr></tbody></table><p>- Keep this leaflet. You may need to read it again.</p><p><strong>- Get emergency medical help immediately if you:</strong></p><ul><li>have trouble breathing, or have slow or shallow breathing</li><li>have a slow heartbeat</li><li>have severe sleepiness</li><li>have cold, clammy skin</li><li>feel faint, dizzy, confused, or cannot think, walk, or talk normally</li><li>have a seizure</li><li>have hallucinations</li></ul><p>&nbsp;</p><p><u><strong>a- What the medication is used for:</strong></u></p><p>Your doctor has prescribed FENTANYL TRANSDERMAL SYSTEM to help control the chronic (long-lasting) pain you are experiencing. Fentanyl is a very strong opioid narcotic pain medicine that can cause serious and life-threatening breathing problems. Serious and life-threatening breathing problems can happen because of an overdose or if the dose you are using is too high for you.</p><p>&nbsp;</p><p><u><strong>b- What it does:</strong></u></p><p><u>What is FENTANYL TRANSDERMAL SYSTEM?</u><br />FENTANYL TRANSDERMAL SYSTEM is a thin, adhesive, rectangular patch that is placed on your skin. &nbsp;Fentanyl transdermal system delivers an opioid medicine called fentanyl continuously through the skin and into the bloodstream to control your pain around the clock.</p><p><u>What to expect from FENTANYL TRANSDERMAL SYSTEM?</u><br />Because the medicine in FENTANYL TRANSDERMAL SYSTEM is gradually released from the patch and slowly absorbed through the skin, do not expect immediate pain relief after you apply your first patch. During this initial period, your doctor may ask you to take additional pain medication until you experience the full benefits of FENTANYL TRANSDERMAL SYSTEM.</p><p>While most patients obtain adequate pain relief with FENTANYL TRANSDERMAL SYSTEM, your pain may vary and occasionally break through. This is not unusual. If this occurs, your doctor may prescribe additional pain medication.</p><p>It is important to let your doctor know whether or not your pain is under control. If you frequently need additional short-acting pain medication, or if pain is waking you at night, you may need a change in your FENTANYL TRANSDERMAL SYSTEM dose. If you continue to have pain, call your doctor.</p><p>Always follow your doctor&#39;s instructions carefully and do not change or stop your FENTANYL TRANSDERMAL SYSTEM medication without first consulting with your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>a- Do not use FENTANYL TRANSDERMAL SYSTEM:</strong></u></p><p>Because life-threatening decreases in breathing rate could occur, FENTANYL TRANSDERMAL SYSTEM should not be used:</p><p>&bull; for the relief of pain before or following surgery.<br />&bull; for the relief of pain which is only mild, or expected to last less than several weeks.<br />&bull; if you have acute or severe bronchial asthma.<br />&bull; if you have difficulty in breathing.</p><p>&nbsp;</p><p><u><strong>b- Take special care with FENTANYL TRANSDERMAL SYSTEM:</strong></u></p><p>Do not start on FENTANYL TRANSDERMAL SYSTEM unless you have already been taking a strong opioid medication.</p><p>Because constipation is a side-effect of opioids, FENTANYL TRANSDERMAL SYSTEM should not be used if you have a type of intestinal blockage known as &quot;paralytic ileus&quot;.</p><p>FENTANYL TRANSDERMAL SYSTEM is not for children under 18 years of age unless your doctor has decided otherwise.</p><p>Do not use FENTANYL TRANSDERMAL SYSTEM if you know you are hypersensitive to fentanyl, other opioid-type medications, or any of the non-medicinal ingredients.</p><p>&nbsp;</p><p><strong>Before using FENTANYL TRANSDERMAL SYSTEM be sure to tell your doctor:</strong></p><ul><li>if you have any other medical conditions (such as diseases of the heart, lung, brain, liver and kidney),</li><li>if you have pancreatitis, or other biliary tract diseases,</li><li>if you are pregnant or plan to become pregnant, are breastfeeding,</li><li>if you are taking any other medications (see Using other medicines, herbal or dietary supplements),</li><li>if you have ever had an allergic reaction to any other medication,</li><li>if you have a head injury or brain tumor,</li><li>if you have a history of drug abuse,</li><li>if you have chronic and severe constipation,</li><li>if you suffer from alcoholism.</li></ul><p>This will help your doctor decide whether you should use FENTANYL TRANSDERMAL SYSTEM and what extra care should be taken during its use.</p><p>&nbsp;</p><p><u><strong>Fever/exposure to heat sources</strong></u><br />At high temperatures, greater than usual quantities of fentanyl can be released into your body. If you have a fever, you should contact your doctor, who may adjust your dose if necessary. Increased release of fentanyl can also result from direct exposure to heat sources. While wearing FENTANYL TRANSDERMAL SYSTEM you should not expose the patch area to sources of heat such as heating pads, electric blankets, heated water beds, heat lamps, saunas and hot tubs, intensive sunbathing, etc., as this may increase the drug&#39;s ability to go through the skin and therefore result in an overdose. This may also occur if you develop a fever.</p><p>&nbsp;</p><p><u><strong>Tolerance</strong></u><br />FENTANYL TRANSDERMAL SYSTEM may lead to tolerance in the long run. It is therefore possible that your doctor will prescribe a higher dose of FENTANYL TRANSDERMAL SYSTEM after some time to produce the same result.</p><p>&nbsp;</p><p><u><strong>Dependence</strong></u><br />There is a possibility that you may become dependent on FENTANYL TRANSDERMAL SYSTEM (fentanyl) with longer term use. Discuss with your doctor.</p><p>&nbsp;</p><p><u><strong>c- Using other medicines, herbal or dietary supplements:</strong></u></p><p>Tell your doctor about all the medications you take. Some medicines may cause serious or life-threatening side effects when used with FENTANYL TRANSDERMAL SYSTEM. Your doctor will tell you if it is safe to take other medications while you are using FENTANYL TRANSDERMAL SYSTEM.</p><p>Know the medicines you take. Keep a list of your medicines to show to your doctor and pharmacist.</p><p>It is extremely important to avoid alcohol and such medications as tranquilizers and sleeping pills when you are using FENTANYL TRANSDERMAL SYSTEM since their combined effect may cause drowsiness, depressed breathing, low blood pressure and possibly coma.</p><p>To avoid any potential drug interactions, be sure to inform your doctor before taking any other medications while you are using FENTANYL TRANSDERMAL SYSTEM, including:</p><ul><li>certain antifungal drugs (e.g. ketoconazole),</li><li>certain antiviral drugs (e.g. ritonavir),</li><li>some antibiotics (e.g. clarithromycin),&nbsp;</li><li>monoamine (MAO) inhibitors (e.g. phenelzine sulfate, tranylcypromine sulfate, moclobemide or selegiline), You should not use fentanyl within 14 days of stopping these medicines&nbsp;</li><li>over-the-counter medications that may cause drowsiness (e.g. antihistamines),</li><li>muscle relaxants,</li><li>anesthetics,</li><li>sedatives or hypnotics,</li><li>phenothiazines,</li><li>other opioid pain medication.</li></ul><p>Drugs that cause a decrease in the ability of the liver to break down drugs including opioids can result in high levels of opioid in the bloodstream when taken at the same time as the patch is used. These drugs include some anti-fungals, some antibiotics, and some anti-viral medications. Talk to your doctor before starting FENTANYL TRANSDERMAL SYSTEM if you are on one of these drugs.</p><p>&nbsp;</p><p><u><strong>d- Using TRANSDERMAL SYSTEM with food and drink:</strong></u></p><p>Food/meals have no influence because FENTANYL is absorbed through skin.</p><p>&nbsp;</p><p><u><strong>e- Pregnancy and breast-feeding</strong></u><br />&nbsp;<br />Use of FENTANYL TRANSDERMAL SYSTEM during childbirth is not recommended because fentanyl passes through the placenta and may cause respiratory depression in the newborn child.</p><p>Fentanyl is excreted in human milk, therefore FENTANYL TRANSDERMAL SYSTEM is not recommended for use in nursing women because of the possibility of effects in their infants.<br />FENTANYL TRANSDERMAL SYSTEM should not be used in women of childbearing potential unless, in the judgment of the physician, the potential benefits outweigh the possible hazards.</p><p>&nbsp;</p><p><u><strong>f- Driving and using machines:</strong></u></p><p>Do not drive a car or operate machinery until you are sure that using the patch does not make you drowsy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You should already be taking some type of strong opioid medication before you begin using FENTANYL TRANSDERMAL SYSTEM patches.</p><p>Your doctor will determine the strength of FENTANYL TRANSDERMAL SYSTEM you should use based on your own particular needs. Do not change your dose without consulting your doctor. Do not wear more than one FENTANYL TRANSDERMAL SYSTEM patch at a time, unless your doctor tells you to do so. Each patch can be used for up to 72 hours (3 days).</p><p>Do not use FENTANYL TRANSDERMAL SYSTEM if the patch is torn upon purchasing, or if the patch is cut, damaged, or changed in any way.</p><p>&nbsp;</p><p><u><strong>Where to apply FENTANYL TRANSDERMAL SYSTEM</strong></u></p><p>Select a dry, non-hairy area on your chest, back, flank or upper arm. If the area you choose has body hair, clip (do not shave) the hair close to the skin with scissors.</p><p>Do not put the patch on skin that is excessively oily, burned, broken out, cut, irritated or damaged in any way. If you need to clean the skin where the patch will be applied, use only clear water. Soaps, oils, lotions, alcohol or other products may irritate the skin under the patch.</p><p>&nbsp;</p><p><u><strong>How to apply FENTANYL TRANSDERMAL SYSTEM</strong></u></p><p>Step 1. Each patch is sealed in its own protective pouch. Do not remove the patch from the pouch until you are ready to use it. When you are ready, tear open the pouch at the notched corner.</p><p>&nbsp;<img width="73" height="58" alt="" src="data:image/jpeg;base64,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" /></p><p>Step 2. A stiff protective liner covers the sticky side of the patch - the side that will be put on your skin. Hold the liner at the edge and pull the patch from the liner. Try not to touch the sticky side of the patch. Throw away the liner.&nbsp;<br /><img width="96" height="80" alt="" src="data:image/jpeg;base64,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" /></p><p>Step 3. Immediately after you have removed the liner, apply the sticky side of the patch to a dry area of your chest, back, flank or upper arm. Press the patch firmly on your skin with the palm of your hand for about 30 seconds. Not all adhesive products stick to all patients. &nbsp;If the patch does not stick well, or loosens after application, tape only the edges down with first aid tape.&nbsp;</p><p><img width="96" height="86" alt="" src="data:image/jpeg;base64,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" /></p><p>In the event that the patch falls off before 3 days or 72 hours, discard it (Before putting on a new FENTANYL TRANSDERMAL SYSTEM patch, remove the patch you have been wearing. Fold the used patch in half so the sticky side sticks to itself, and flush down the toilet immediately. A used FENTANYL TRANSDERMAL SYSTEM patch can be very dangerous for, or even lead to death in babies, children, pets and adults who have not been prescribed FENTANYL TRANSDERMAL SYSTEM as considerable amount of drug remains in the patch after use. Do not put used FENTANYL TRANSDERMAL SYSTEM patches in a trash can. Wash your hands, with water only, after removing the patch and put a new one on at a different skin site) Be sure to let your doctor know that this has happened, and do not replace the new patch until 3 days (72 hours) after you put it on (or as directed by your doctor).</p><p>Step 4. Wash your hands when you have finished applying the patch.</p><p>Step 5. Special labels are provided to help you remember when you last put on your patch. After putting on the patch, write the date and time on a label, then stick the label on the patch.</p><p>Step 6. After wearing the patch for 3 days, or as directed by your doctor, remove it (like in step 3). Then choose a different place on your skin to apply a new patch and repeat steps 1 to 5 in order.</p><p><strong>Do not apply the new patch to the same place as the last one.</strong></p><p>&nbsp;</p><p><u><strong>Water and FENTANYL TRANSDERMAL SYSTEM</strong></u></p><p>You can bathe, swim, or shower while you are wearing FENTANYL TRANSDERMAL SYSTEM. If the patch falls off, discard the patch properly (discard it as in step 3) and apply a new one at a different skin site, making sure the new skin area you choose is dry. Be sure to let your doctor know that this has happened, and do not replace the new patch until 3 days (72 hours) after you put it on (or as directed by your doctor).</p><p>&nbsp;</p><p><u><strong>a- If you take more FENTANYL TRANSDERMAL SYSTEM than you should:</strong></u><br />The most important sign of overdose is suppressed breathing. If a person is breathing abnormally slowly or weakly, remove the patch and seek emergency medical care immediately. Meanwhile, keep the person awake by talking or by shaking him/her every now and then. Other signs of fentanyl overdose may include tiredness, extreme sleepiness or sedation; inability to think, talk or walk normally; and feeling faint, dizzy or confused, seizure and hallucination. In the event of overdosage, contact your doctor, hospital emergency department or regional poison control center.</p><p><u><strong>b- If you forget to use FENTANYL TRANSDERMAL SYSTEM:</strong></u></p><p>If a patch is left on for more than three days (72 hours), remove patch and apply a new patch following instructions given (Please do not suddenly stop taking FENTANYL TRANSDERMAL SYSTEM as it may cause unwanted side effects, such as nausea, vomiting, diarrhea, anxiety, and shivering. Your doctor can discuss the best way for you to stop taking FENTANYL TRANSDERMAL SYSTEM).</p><p><u><strong>c- If you stop using FENTANYL TRANSDERMAL SYSTEM:</strong></u></p><p>Opioid withdrawal symptoms, such as nausea, vomiting, diarrhea, anxiety and shivering are possible after converting from your previous opioid analgesic to FENTANYL TRANSDERMAL SYSTEM, or converting from FENTANYL TRANSDERMAL SYSTEM to another opioid. Contact your doctor if you experience these symptoms when switching to or from FENTANYL TRANSDERMAL SYSTEM and DO NOT STOP USING FENTANYL TRANSDERMAL SYSTEM SUDDENLY.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medications, FENTANYL TRANSDERMAL SYSTEM may cause unwanted effects. Most unwanted effects appear during the first month of treatment. These effects may be more pronounced if you have a fever. If you develop a fever while using the patch, contact your doctor right away.</p><p>The most frequently reported unwanted effects are nausea, vomiting, tiredness, constipation, sweating, dizziness, headache, dry mouth, confusion, depression and skin irritation at the application site.</p><p>Slowed breathing has been reported by a small number of patients using fentanyl transdermal system. If this occurs, seek emergency medical care immediately. Be aware that removing the patch does not completely remove the source of drug, as drug is deposited under the skin and will continue to be released into the bloodstream over the next hours after the patch is removed.</p><p>Serious and life-threatening breathing problems can happen because of an overdose or if the dose you are using is too high for you (see Section 3). If breathing problems develop, seek emergency medical care immediately.</p><p>There have been very rare reports of serious allergic reactions, such as Stevens-Johnson syndrome (rash and fever or sore eyes/mouth), airway constriction, swelling, and anaphylactic shock. In one case, it was the patient caretaker who experienced the allergic reaction, from applying the patch to the patient. If these symptoms develop, contact your doctor immediately.</p><p>There have been rare reports of seizures (convulsions) in people using FENTANYL TRANSDERMAL SYSTEM. If you notice anything unusual, please contact your doctor immediately. This is not a complete list of side effects. For any unexpected effects while taking FENTANYL TRANSDERMAL SYSTEM contact your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the reach and sight of children.</li><li>Keep FENTANYL TRANSDERMAL SYSTEM in its protective pouch until you are ready to use it.&nbsp;</li><li>Store FENTANYL TRANSDERMAL SYSTEM below 25&deg;C.&nbsp;</li><li>Do not refrigerate or freeze.&nbsp;</li><li>Remember the inside of your car can reach temperatures much higher than 30&deg;C on a sunny day.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is Fentanyl.<br />&bull; The other ingredients are Backing Layer: polyester film, Adhesive Layer: isopropyl myristate, octyldodecanol, polybutene and polyisobutene, Release Liner: polyester film</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                FENTANYL TRANSDERMAL SYSTEM is supplied in cartons containing 5 individually packaged systems. FENTANYL TRANSDERMAL SYSTEM comes in four strengths: 2.76 mg, 5.52 mg, 8.28 mg, and 11.04 mg fentanyl per patch, delivering 25, 50, 75, and 100 mcg fentanyl per hour respectively for 72 hours.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder<br />Apotex Inc., Toronto, Ontario, M9L 1T9 Canada</p><p>Manufacturer<br />AVEVA DRUG DELIVERY SYSTEM, INC., Miramar, FL 33025</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;إذا كانت لديك أي استفسارات بخصوص الدواء، اتصل بطبيبك أو الصيدلي.</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><ul><li>يحفظ نظام لاصقة الفنتانيل الجلدية في مكان آمن بعيدًا عن الأطفال والحيوانات الأليفة. الاستخدام غير المقصود بواسطة الأطفال أو الحيوانات الأليفة يعد حالة طبية طارئة وقد يؤدي إلى الوفاة. إذا استخدم طفل أو حيوان أليف نظام لاصقة الفنتانيل الجلدية بشكل غير مقصود، اطلب المساعدة الطبية الطارئة على الفور.</li><li>لا تستخدم لاصقة نظام لاصقة الفنتانيل الجلدية إذا كان ختم اللاصقة مكسورًا، أو إذا كانت اللاصقة مقطوعة أو تالفة أو تغيرت بأي شكل من الأشكال.</li><li>تأكد من أنك قد قرأت قسم &quot;طريقة الاستخدام&quot;. اتبع التعليمات واستخدم دائمًا لاصقة نظام لاصقة الفنتانيل الجلدية بالطريقة الصحيحة. قد يسبب نظام لاصقة الفنتانيل الجلدية مشاكل خطيرة في التنفس والوفاة، خاصة إذا تم استخدامه بطريقة غير صحيحة.</li><li>أخبر طبيبك إذا كنت أنت (أو أحد أفراد أسرتك) مدمنًا أو معتمدًا على الكحول أو الأدوية التي تصرف بوصفة طبية أو المخدرات.&nbsp;</li></ul></td></tr></tbody></table><p>- احتفظ بهذه النشرة لأنك قد تحتاج إليها لاحقاً.</p><p><strong>- اطلب المساعدة الطبية الطارئة إذا كنت:</strong></p><ul><li>تعاني من مشاكل في التنفس، أو بطء التنفس أو ضيق التنفس.</li><li>تعاني من بطء ضربات القلب</li><li>تعاني من نعاس شديد</li><li>تعاني من البرد أو الجلد الرطب</li><li>تشعر بالضعف، الدوار، التشوش، أو عدم القدرة على التفكير أو المشي أو التحدث بشكل طبيعي</li><li>تعاني من نوبات صرعية</li><li>مصابًا بهلاوس</li></ul><p>&nbsp;</p><p><u><strong>أ- في ماذا يستعمل هذا الدواء:</strong></u></p><p>طبيبك قام بصرف دواء نظام لاصقة الفنتانيل الجلدية للمساعدة في السيطرة على الألم المزمن (طويل الأمد) الذي كنت تواجهه. الفنتانيل هو من الأدوية الافيونية القوية جداً والمخدرة للألم التي يمكن أن تسبب مشاكل في التنفس خطيرة ومهددة للحياة. يمكن أن يحدث مشاكل في التنفس خطيرة ومهددة للحياة بسبب جرعة زائدة أو إذا كنت تستخدم جرعة قد تكون مرتفعة جداً بالنسبة لك.</p><p>&nbsp;</p><p><u><strong>ب- ماذا يفعل هذا الدواء:</strong></u></p><p><u>ما هو نظام لاصقة الفنتانيل الجلدية؟</u></p><p><strong>نظام لاصقة الفنتانيل الجلدية</strong> عبارة عن لاصقة جلدية رقيقة مستطيلة الشكل تحتوي على الفنتانيل. الفنتانيل هو مسكن ومخدر أفيوني قوي جدًا لعلاج الألم.</p><p>&nbsp;</p><p><u>ما الذي يمكن توقعه من نظام لاصقة الفنتانيل الجلدية&nbsp;</u></p><p>بسبب إطلاق الدواء الموجود داخل لاصقة <strong>نظام لاصقة الفنتانيل الجلدية</strong> بشكل تدريجي من اللاصقة وامتصاصه ببطء عبر الجلد، ينبغي ألا تتوقع تخفيفًا فوريًا للألم بعد استعمال أول لاصقة. &nbsp;خلال الفترة الأولى من استخدام اللاصقة، قد يطلب منك طبيبك تناول أدوية أخرى مضادة للألم إلى أن تشعر بالفائدة الكاملة <strong>لنظام لاصقة الفنتانيل الجلدية</strong>.</p><p>بينما يحصل معظم المرضى على تخفيف كافٍ للألم عند استخدام <strong>نظام لاصقة الفنتانيل الجلدية</strong>، فقد يكون الألم لديك مختلفًا وينطلق الشعور بالألم مرة أخرى بين حين وآخر. إن هذا الأمر غير معتاد. إذا حدث ذلك، فقد يصف لك طبيبك أدوية أخرى للألم.</p><p>من المهم أن تخبر طبيبك ما إذا كان الألم لديك تحت التحكم أم لا. إذا كنت تحتاج بشكل متكرر إلى أدوية قصيرة المفعول لتخفيف الألم، أو إذا كنت تستيقظ ليلاً بسبب الألم، فقد تحتاج لتغيير جرعة <strong>نظام لاصقة الفنتانيل الجلدية</strong>. إذا استمر الألم، <strong>اتصل بطبيبك</strong>.<br />&nbsp;<br />اتبع دائمًا تعليمات الطبيب بعناية ولا تغير أو توقف دواء <strong>نظام لاصقة الفنتانيل الجلدية </strong>دون استشارة طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>أ- موانع استخدام نظام لاصقة الفنتانيل الجلدية:</strong></u></p><p><strong>بسبب نقص معدل التنفس المهدد للحياة والذي يمكن أن يحدث بسبب الدواء، يجب عدم استخدام نظام لاصقة الفنتانيل الجلدية في الحالات التالية:</strong></p><p>&bull; تخفيف الألم قبل أو بعد إجراء جراحة.<br />&bull; تخفيف الألم الخفيف، أو الألم الذي يتوقع أن يستمر أقل من عدة أسابيع.<br />&bull; إذا كنت تعاني من ربو شعبي حاد أو شديد.<br />&bull; إذا كنت تعاني من صعوبة في التنفس.</p><p>&nbsp;</p><p><u><strong>ب- الاحتياطات عند استعمال نظام لاصقة الفنتانيل الجلدية:</strong></u></p><p>لنفس السبب، لا تبدأ في تعاطي <strong>نظام لاصقة الفنتانيل الجلدية</strong> ما لم تكن قد تناولت بالفعل دواءً أفيونيًا قويًا. لأن الإمساك هو أثر جانبي للأفيونات، فإنه يجب عدم استخدام <strong>نظام لاصقة الفنتانيل الجلدية</strong> إذا كنت مصابًا بنوع من الانسداد المعوي يعرف بـ &quot;العلوص الشللي&quot;.</p><p>يجب عدم استخدام نظام لاصقة الفنتانيل الجلدية في الأطفال الذين تقل أعمارهم عن 18 عامًا ما لم يقرر طبيبك خلاف ذلك.</p><p>لا تستخدم <strong>نظام لاصقة الفنتانيل الجلدية</strong> إذا كنت مصابًا بفرط الحساسية للفنتانيل، أو أي أدوية أفيونية أخرى، أو لأي من المكونات غير الطبية (انظر المكونات غير الطبية).</p><p>قبل استخدام نظام لاصقة الفنتانيل الجلدية تأكد من إخبار طبيبك:</p><ul><li>إذا كنت مصابًا بأي حالة طبية أخرى (مثل أمراض القلب، الرئة، الدماغ، الكبد، الكلى).</li><li>إذا كنت مصابًا بالتهاب البنكرياس أو أمراض أخرى في السبيل الصفراوي.</li><li>إذا كنتِ حامل أو تخططين للحمل، أو كنتِ ترضعين رضاعة طبيعية</li><li>إذا كنت تتناول أي أدوية أخرى (انظر &quot;التداخلات الدوائية من أخذ هذا المستحضر مع أي ادوية اخرى او اعشاب او مكملات غذائية&quot;)</li><li>إذا أصبت من قبل بتفاعل حساسية لأي دواء آخر</li><li>إذا أصبت بإصابة في الرأس أو ورم في الدماغ</li><li>إذا كان لديك تاريخ من إساءة استخدام الأدوية&nbsp;</li><li>إذا كنت تعاني من إمساك مزمن أو شديد</li><li>إذا كنت تعاني من إدمان الكحوليات.</li></ul><p>سوف يساعد ذلك طبيبك على اتخاذ قرار بخصوص ما إذا كان بإمكانك استخدام <strong>نظام لاصقة الفنتانيل الجلدية</strong>، وبخصوص الرعاية الإضافية التي ينبغي اتخاذها أثناء الاستخدام.</p><p>&nbsp;</p><p><u><strong>الحمى/التعرض لمصادر الحرارة</strong></u></p><p>عند درجات الحرارة العالية، قد يتم إطلاق كميات من الفنتانيل أعلى من الكميات التي يتم إطلاقها في المعتاد في جسدك. إذا كنت تعاني من حمى، يجب عليك الاتصال بطبيبك، والذي قد يعدل جرعتك عند الحاجة. وقد تنتج الزيادة في إطلاق الفنتانيل أيضًا عن التعرض المباشر لمصادر الحرارة. أثناء ارتداء لاصقة نظام لاصقة الفنتانيل الجلدية يجب عدم تعريض منطقة اللاصقة لمصادر حرارة مثل وسائد التدفئة، البطانيات الكهربائية، أسِّرة المياه الدافئة، المصابيح الحرارية، الساونا وبانيوهات الماء الساخن، حمامات الشمس المكثفة ...إلى آخره، حيث أن ذلك قد يزيد من قدرة الدواء على المرور عبر الجلد ومن ثمّ يسبب الجرعة الزائدة. قد يحدث ذلك أيضًا إذا أصبت بحمى.</p><p>&nbsp;</p><p><u><strong>التحمل</strong></u></p><p>ويقصد به تدنّي التجاوب الفسيولوجي مع تكرار تناول الدواء ذاته مما يؤدي الى &nbsp;الحاجة إلى زيادة الجرعة للإبقاء على تأثير ثابت. قد يؤدي نظام لاصقة الفنتانيل الجلدية إلى زيادة التحمل عند التعاطي طويل الأمد. لذلك من المرجح أن يصف لك طبيبك جرعة أعلى من نظام لاصقة الفنتانيل الجلدية بعد مرور بعض الوقت للحصول على نفس النتيجة.</p><p>&nbsp;</p><p><u><strong>الاعتماد</strong></u></p><p>من الممكن أن تصبح معتمدًا على نظام لاصقة الفنتانيل الجلدية (فنتانيل) مع الاستخدام طويل الأمد. ناقش ذلك مع طبيبك.</p><p>&nbsp;</p><p><u><strong>ج- التداخلات الدوائية من أخذ هذا المستحضر مع أي ادوية اخرى او اعشاب او مكملات غذائية:</strong></u></p><p>أخبر طبيبك عن جميع الأدوية التي تتناولها. بعض الأدوية قد تسبب آثارًا جانبية خطيرة أو مهددة للحياة عند استخدامها مع نظام لاصقة الفنتانيل الجلدية. سوف يخبرك طبيبك عن ما إذا كان تناول أدوية أخرى أثناء استخدام نظام لاصقة الفنتانيل الجلدية آمنًا أم لا.<br />&nbsp;<br />كن على علم بالأدوية التي تتناولها. احتفظ بقائمة الأدوية التي تتناولها لعرضها على طبيبك والصيدلي.</p><p>من المهم للغاية تجنب تناول الكحول وأدوية مثل المهدئات والحبوب المنومة أثناء تناول نظام لاصقة الفنتانيل الجلدية، حيث قد يؤدي تأثيرها المجمَّع إلى النعاس، تثبيط التنفس، انخفاض ضغط الدم، وقد ينتج عن ذلك الإصابة بالغيبوبة.</p><p>لتجنب أي تفاعلات دوائية محتملة، تأكد من إبلاغ طبيبك قبل تناول أي أدوية أخرى أثناء استخدام <strong>نظام لاصقة الفنتانيل الجلدية</strong>، ويضم ذلك:</p><ul><li>أدوية معينة مضادة للفطريات (مثل كيتوكونازول)</li><li>أدوية معينة مضادة للفيروسات (مثل ريتونافير)</li><li>بعض المضادات الحيوية (مثل كلاريثرومايسين)،&nbsp;</li><li>مثبطات المونوأمين أكسيداز (MAO) (مثل فينيلزين سلفات، ترانيل سيبرومين سلفات، موكلوبيميد، سيليجيلين) يجب عدم استخدام نظام لاصقة الفنتانيل الجلدية خلال 14 يوم من التوقف عن استخدام هذه المستحضرات</li><li>الأدوية التي تصرف دون وصفة طبية التي يمكن أن تسبب النعاس (مثل مضادات الهستامين)</li><li>مرخيات العضلات</li><li>المسكنات</li><li>الأدوية المهدئة أو المنومة</li><li>مركبات الفينوثيازين</li><li>الأدوية الأفيونية الأخرى المضادة للألم.</li></ul><p>قد تؤدي الأدوية التي تسبب نقص قدرة الكبد على تكسير الأدوية بما في ذلك الأفيونات لارتفاع مستويات الأفيونات في مجرى الدم عند تناولها في نفس وقت استخدام اللاصقة. تضم هذه الأدوية بعض مضادات الفطريات، وبعض المضادات الحيوية، وبعض الأدوية المضادة للفيروسات. تحدث إلى طبيبك قبل البدء في استخدام نظام لاصقة الفنتانيل الجلدية إذا كنت تتناول أحد هذه الأدوية.</p><p>&nbsp;</p><p><u><strong>د- استخدام نظام لاصقة الفنتانيل الجلدية مع الطعام والشراب:</strong></u></p><p>الطعام والشراب ليس لها تأثير لأن الفنتانيل يمتص عبر الجلد.</p><p>&nbsp;</p><p><u><strong>هـ- الحمل والرضاعة:</strong></u></p><p>استخدام نظام لاصقة الفنتانيل الجلدية أثناء فترة الحمل غير مستحسن لأن الفنتانيل يمر عبر المشيمة ويمكن أن يسبب تثبيط للجهاز التنفسي في الأطفال حديثي الولادة.</p><p>يفرز الفنتانيل في اللبن البشري، فمن غير المستحسن استخدام <strong>نظام لاصقة الفنتانيل الجلدية</strong> في النساء المرضعات بسبب احتمال تأثيره في أطفالهن الرضع.</p><p>لا ينبغي أن تستخدم <strong>نظام لاصقة الفنتانيل الجلدية</strong> في النساء اللواتي يفكرن في الإنجاب، إلا إذا قرر الطبيب ان الفوائد المحتملة تفوق المخاطر المحتملة.</p><p>&nbsp;</p><p><u><strong>و- تأثير نظام لاصقة الفنتانيل الجلدية على القيادة واستخدام الآلات:</strong></u></p><p>لا تقم بقيادة سيارة أو تشغيل ماكينة إلا بعد أن تكون متأكدًا من أن اللاصقة لا تجعلك تشعر بالدوار.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب أن تتناول أحد أنواع الأدوية الأفيونية القوية قبل أن تبدأ في استخدام لاصقات <strong>نظام لاصقة الفنتانيل الجلدية</strong>.</p><p>سوف يحدد طبيبك جرعة <strong>نظام لاصقة الفنتانيل الجلدية</strong> التي ينبغي عليك استخدامها بناءً على احتياجاتك الخاصة. لا تغير الجرعة دون استشارة طبيبك. لا ترتدي أكثر من لاصقة <strong>نظام لاصقة الفنتانيل الجلدية</strong> واحدة في نفس الوقت ما لم يطلب منك طبيبك خلاف ذلك. يمكن استخدام كل لاصقة لمدة تصل إلى 72 ساعة (<strong>3</strong> أيام).</p><p>لا تستخدم لاصقة <strong>نظام لاصقة الفنتانيل الجلدية</strong> إذا كان الغلاف ممزقًا عند الشراء، أو إذا كانت اللاصقة مقطوعة أو تالفة أو متغيرة بأي شكل.</p><p>&nbsp;</p><p><u><strong>موضع استخدام نظام لاصقة الفنتانيل الجلدية</strong></u></p><p>اختر منطقة جافة لا يوجد بها شعر في الصدر أو الظهر أو الخاصرة أو أعلى الذراع. إذا كانت المنطقة التي اخترت وضع اللاصقة بها شعر، قم بقص (وليس حلق) الشعر القريب من الجلد باستخدام مقص.</p><p>لا تضع اللاصقة على الجلد الدهني بشكل مفرط، أو الجلد المحترق، أو الذي يحتوي على بثور أو المقطوع أو المتهيج أو التالف بأي شكل من الأشكال. إذا كانت هناك حاجة لتنظيف الجلد الذي ستضع عليه اللاصقة، استخدم الماء النظيف فقط. قد تؤدي أنواع الصابون أو اللوسيونات أو الكحول أو المنتجات الأخرى إلى تهيج الجلد تحت اللاصقة.</p><p>&nbsp;</p><p><u><strong>كيفية استخدام نظام لاصقة الفنتانيل الجلدية</strong></u><br />&nbsp;<br />الخطوة 1:<br />تم لحم كل لاصقة في الجراب الواقي. لا تقم بنزع اللاصقة من الجراب إلا عندما تكون جاهزًا لاستخدامها. عندما تكون جاهزًا، افتح الجراب من الجانب المحزز. &nbsp;</p><p><img width="73" height="58" alt="" src="data:image/jpeg;base64,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" /></p><p>الخطوة 2: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br />هناك بطانة واقية صلبة تغطي الجانب اللاصق من اللاصقة &ndash; الجانب الذي يتم وضعه على الجلد. أمسك البطانة من الحافة واسحب اللاصقة من البطانة. حاول عدم لمس الجزء اللاصق من اللاصقة. تخلص من البطانة.</p><p><img width="96" height="80" alt="" src="data:image/jpeg;base64,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" /></p><p>الخطوة 3:&nbsp;<br />بعد أن تنزع البطانة، قم على الفور بوضع الجزء اللاصق على منطقة جافة في الصدر أو الظهر أو الخاصرة أو أعلى الذراع. اضغط اللاصقة بإحكام على الجلد باستخدام راحة اليد لمدة 30 ثانية تقريبًا.</p><p><img width="96" height="86" alt="" src="data:image/jpeg;base64,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" /></p><p>لا تلتصق جميع المنتجات اللاصقة بالجلد لدى جميع المرضى. إذا لم تلتصق اللاصقة جيدًا أو إذا تفككت بعد الاستخدام، اربط الحواف فقط باستخدام شريط لاصق. في حالة سقوط اللاصقة قبل مرور 3 أيام أو 72 ساعة، تخلص منها (&quot;التخلص من نظام لاصقة الفنتانيل الجلدية&quot;) قبل وضع لاصقة نظام لاصقة الفنتانيل الجلدية جديدة، انزع اللاصقة التي ترتديها. قم بطي اللاصقة المستعملة إلى نصفين بحيث يلتصق الجانب اللاصق ببعضه البعض، ثم تخلص منها عبر المرحاض على الفور. &nbsp;</p><p><strong>لاصقة نظام لاصقة الفنتانيل الجلدية المستعملة قد تكون خطيرة جدًا، أو قد تؤدي إلى الوفاة ،على الرضع والأطفال والبالغين الذين لم يتم وصف نظام لاصقة الفنتانيل الجلدية لهم، حيث أن كمية كبيرة من الدواء تبقى في اللاصقة بعد استخدامها. لا تضع لاصقة نظام لاصقة الفنتانيل الجلدية المستعملة في صندوق القمامة.</strong></p><p><strong>بعد نزع اللاصقة، اغسل يديك بالماء فقط.</strong></p><p>تخلص من أي لاصقات تتبقى من وصفتك الطبية بمجرد انتهاء الحاجة لاستخدامها. انزع اللاصقات المتبقية من الجراب الواقي وانزع البطانة الواقية. قم بطي اللاصقات إلى نصفين وتخلص منها في المرحاض. لا تتخلص من الجراب أو البطانة الواقية في المرحاض.</p><p>تحتوي لاصقة <strong>نظام لاصقة الفنتانيل الجلدية</strong> على الفنتانيل، وهو دواء تكون احتمالية إدمانه مرتفعة. تحتوي اللاصقات التي قمت بالتخلص منها على كمية كبيرة من الدواء، ويعد التخلص منها في المرحاض طريقة فعالة لمنع سرقتها أو إساءة استخدامها من قِبَل آخرين. وضع لاصقة جديدة في موضع آخر من الجلد. تأكد من إخبار طبيبك بذلك، ولا تستبدل اللاصقة الجديدة قبل مرور 3 أيام (72 ساعة) على وضعها (أو حسب توجيهات طبيبك).</p><p>الخطوة 4:</p><p>اغسل يديك عند الانتهاء من وضع اللاصقة.</p><p>الخطوة 5:</p><p>يتم التزويد بملصقات خاصة لمساعدتك.<br />تذكر الوقت الذي وضعت فيه آخر لاصقة. بعد وضع اللاصقة، اكتب التاريخ والوقت على أحد هذه الملصقات، ثم ضع الملصق على اللاصقة.</p><p>الخطوة 6:</p><p>بعد ارتداء اللاصقة لمدة 3 أيام، أو حسب توجيهات طبيبك ،قم بنزعها (<strong>انظر &quot;التخلص من نظام لاصقة الفنتانيل الجلدية&quot;</strong>). بعد ذلك قم باختيار موضع مختلف على الجلد لوضع لاصقة جديدة وكرر الخطوات من 1 إلى 5 بالترتيب.</p><p><br /><strong>لا تضع اللاصقة الجديدة في نفس موضع اللاصقة الأخيرة.</strong><br />&nbsp;</p><p><br /><u><strong>الماء ونظام لاصقة الفنتانيل الجلدية</strong></u></p><p>يمكنك الاستحمام أو السباحة أو أخذ دش أثناء ارتداء نظام لاصقة الفنتانيل&nbsp;الجلدية. &nbsp;إذا سقطت اللاصقة، تخلص منها بشكل صحيح (انظر &quot;التخلص من نظام لاصقة الفنتانيل الجلدية&quot;) واستخدم لاصقة أخرى في موضع آخر من الجلد، مع التأكد من أن المنطقة الجديدة التي اخترتها جافة. تأكد من إخبار طبيبك بذلك، ولا تستبدل اللاصقة الجديدة قبل مرور 3 أيام (72 ساعة) على وضعها (أو حسب توجيهات طبيبك).</p><p>&nbsp;</p><p><u><strong>أ- الجرعة الزائدة من نظام لاصقة الفنتانيل الجلدية:</strong></u></p><p>أهم علامة من علامات الجرعة الزائدة هي تثبيط التنفس. إذا كان أحد الأشخاص يتنفس بشكل غير طبيعي ببطء أو ضعف، انزع اللاصقة واطلب المساعدة الطبية الطارئة على الفور. أثناء ذلك، اجعل هذا الشخص مستيقظًا عن طريق التحدث معه أو هزه بين حين وآخر.العلامات الأخرى للجرعة الزائدة من الفنتانيل قد تتضمن: التعب، النعاس أو السكون المفرط، عدم القدرة على التفكير أو التحدث أو المشي بشكل طبيعي، الشعور بالضعف أو الدوار أو التشوش، النوبات الصرعية، الهلوسة. في حالة الجرعة الزائدة، اتصل بطبيبك أو قسم الطوارئ بالمستشفى أو المركز الإقليمي لمكافحة السموم.</p><p>&nbsp;</p><p><u><strong>ب- نسيان استخدام نظام لاصقة الفنتانيل الجلدية:</strong></u></p><p>إذا تم ترك اللاصقة لمدة تزيد عن ثلاثة أيام (72 ساعة)، انزع اللاصقة واستخدم أخرى جديدة مع اتباع التعليمات الواردة في قسم (طريقة استخدام نظام لاصقة الفنتانيل الجلدية).</p><p>&nbsp;</p><p><u><strong>ج- التوقف عن استخدام نظام لاصقة الفنتانيل الجلدية:</strong></u></p><p>برجاء عدم التوقف عن استخدام نظام لاصقة الفنتانيل الجلدية بشكل مفاجئ، حيث أن ذلك قد يسبب آثارًا جانبية غير مرغوبة مثل الغثيان والقيء والإسهال والقلق والارتعاش. قد يناقش طبيبك معك أفضل طريقة لوقف استخدام نظام لاصقة الفنتانيل الجلدية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><br />مثل جميع الأدوية، قد يسبب نظام لاصقة الفنتانيل الجلدية آثارًا غير مرغوبة. معظم الآثار غير المرغوبة تظهر خلال الشهر الأول من العلاج. قد تظهر هذه الآثار بشكل أوضح إذا كنت مصابًا بحمى. إذا أصبت بحمى أثناء استخدام اللاصقة، اتصل بطبيبك على الفور.</p><p>أكثر الآثار غير المرغوبة التي تم الإبلاغ عنها تكرارًا هي: الغثيان، القيء، التعب، الإمساك، التعرق، الدوار، الصداع، جفاف الفم، التشوش، الاكتئاب، تهيج الجلد في موضع الاستخدام.</p><p>تم الإبلاغ عن بطء التنفس من قِبَل عدد قليل من المرضى الذين يستخدمون لاصقة الفنتانيل الجلدية. إذا حدث ذلك، اطلب الرعاية الطبية الطارئة على الفور.</p><p>يجب أن تعلم أن نزع اللاصقة لا يزيل مصدر الدواء تمامًا، حيث أن الدواء قد تم ترسيبه تحت الجلد وسوف يستمر إطلاقه إلى مجرى الدم على مدى الساعات التي تعقب نزع اللاصقة.</p><p>&nbsp;</p><p><strong>أعراض انسحاب المركبات الأفيونية</strong><br />&nbsp;<br />يمكن أن تحدث أعراض انسحاب المركبات الأفيونية، مثل الغثيان والقيء والإسهال والقلق والارتعاش ،بعد التحويل من الدواء الأفيوني الذي كنت تتناوله في السابق إلى <strong>نظام لاصقة الفنتانيل الجلدية</strong>، أو بعد التحويل من <strong>نظام لاصقة الفنتانيل الجلدية</strong> إلى دواء أفيوني آخر. اتصل بطبيبك إذا شعرت بهذه الأعراض عند التحويل من أو إلى <strong>نظام لاصقة الفنتانيل الجلدية</strong>.</p><p>قد تحدث مشاكل التنفس الخطيرة المهددة للحياة بسبب الجرعة الزائدة أو إذا كانت الجرعة التي تتناولها أكبر بكثير من الجرعة المناسبة لك (<strong>انظر &quot;الجرعة الزائدة&quot;</strong>). إذا أصبت بمشاكل في التنفس، اطلب الرعاية الطبية الطارئة على الفور.</p><p>كانت هناك تقارير نادرة للغاية عن تفاعلات الحساسية الخطيرة، مثل متلازمة ستيفين-جونسون (طفح وحمى أو تقرح العينين/الفم)، تقلص الشعب الهوائية، التورم، الصدمة التأقية. وفي حالة واحدة، تعرض المشرف على المريض إلى تفاعل حساسية عند وضع اللاصقة للمريض. إذا أصبت بهذه الأعراض، اتصل بطبيبك على الفور.</p><p>كانت هناك تقارير نادرة عن حدوث نوبات صرعية (تشنجات) في المرضى الذين يستخدمون <strong>نظام لاصقة الفنتانيل الجلدية</strong>. إذا لاحظت أي شيء غير طبيعي، برجاء الاتصال بطبيبك على الفور.</p><p><strong>هذه القائمة ليست قائمة كاملة للآثار الجانبية. في حالة ظهور أي آثار غير متوقعة أثناء استخدام نظام لاصقة الفنتانيل الجلدية، اتصل بطبيبك أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يحفظ <strong>نظام لاصقة الفنتانيل الجلدية</strong> بعيدًا عن متناول الأطفال.<br />- يحفظ <strong>نظام لاصقة الفنتانيل الجلدية</strong> داخل الجراب الواقي إلى أن تكون جاهزًا لاستخدامه.&nbsp;<br />- يحفظ <strong>نظام لاصقة الفنتانيل الجلدية</strong> في درجة حرارة أقل من 25 درجة مئوية.&nbsp;<br />- يحظر التبريد أو التجميد.&nbsp;<br />- تذكر أن درجة الحرارة داخل سيارتك قد تتجاوز 30 درجة مئوية في الأيام المشمسة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي الفنتانيل</p><p>&bull; المواد الاخرى هي طبقة التغليف: طبقة من البولي إستر، الطبقة اللاصقة: أيزوبروبيل ميريستات، أوكتيل دوديكانول، بولي بيوتين، بولي أيزوبيوتين، &nbsp;بطانة الإطلاق: طبقة من البولي إستر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتم التزويد <strong>بنظام لاصقة الفنتانيل الجلدية</strong> في عبوات كرتونية تحتوي على <strong>5&nbsp;</strong>لاصقات معبأة بشكل منفرد.<br />&nbsp;<br />ويأتي <strong>نظام لاصقة الفنتانيل الجلدية</strong> في <strong>4 </strong>جرعات:</p><p>2.76 مجم، 5.52 مجم، 8.28 مجم، &nbsp;11.04 مجم فنتانيل في اللاصقة، ويقوم بتوصيل 25 ميكروجرام، 50 ميكروجرام، 75 ميكروجرام، 100 ميكروجرام فنتانيل في الساعة على الترتيب، وذلك لمدة 72 ساعة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك رخصة التسويق</strong><br />شركة أبوتكس، في مدينة تورنتو، مقاطعة أونتاريو، M9L 1T9 كندا</p><p><strong>المصنع</strong><br />شركة افيفا لنظم إعطاء الدواء, ميرامار, فلوريدا 33025</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FENTANYL TRANSDERMAL SYSTEM
25 mcg/h, 50 mcg/h, 75 mcg/h, and 100 mcg/h 
Opioid Analgesic
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FENTANYL TRANSDERMAL SYSTEM is a transdermal patch providing continuous systemic delivery of fentanyl, a potent opioid analgesic, for 72 hours.

FENTANYL TRANSDERMAL SYSTEM is available as 25 mcg/h rectangular unit with round comers consisting of an opaque tan backing imprinted overall with "Fentanyl 25 mcg/hr" in pink. 
The 50 mcg/h rectangular unit is imprinted overall with "Fentanyl 50 mcg/hr" in green. 
The 75 mcg/h rectangular unit is imprinted overall with "Fentanyl 75 mcg/hr" in teal. 
The 100 mcg/h rectangular unit is imprinted overall with "Fentanyl 100 mcg/hr" in gray.

FENTANYL TRANSDERMAL SYSTEM is comprised of a release liner, a functional layer and a backing. Proceeding from the outer surface towards the surface adhering to the skin, these layers are 1) a backing layer of polyethylene/aluminum/polyester film, 2) an adhesive matrix containing isopropyl myristate, octyldodecanol, polybutene and polyisobutene and the active ingredient, fentanyl and 3) a protective release liner made of polyester. The peelable release liner must be removed before the system can be applied.
 
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FENTANYL TRANSDERMAL SYSTEM is available in four different strengths. Each system is labeled with a nominal flux which represents the average amount of drug delivered to the systemic circulation per hour across average skin. The active component of the system is fentanyl. The
amount of fentanyl released from each system per hour is proportional to the surface area (25 mcg/h per 10 cm2). The 10.7, 21.4, 32.1 and 42.8 cm2 systems are designed to deliver 25, 50, 75 or
100 mcg/h fentanyl to the systemic circulation, representing approximately 0.6, 1.2, 1.8 or 2.4 mg per day, respectively. The remaining components are pharmacologically inactive.

Total fentanyl contents and system sizes for the four strengths are summarized below:

Fentanyl delivery rate (mcg/h) Total fentanyl content (mg)     System size (cm2)
25	                                                                      2.76	                                      10.7
50	                                                                      5.52	                                      21.4
75	                                                                      8.28	                                      32.1
100	                                                                     11.04	                                      42.8

FENTANYL TRANSDERMAL SYSTEM is supplied in cartons containing 5 individually packaged systems.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp; </strong><strong><u>Adults</u></strong></p><p>FENTANYL TRANSDERMAL SYSTEM is a transdermal formulation of fentanyl indicated for</p><p>the management of persistent, moderate to severe chronic pain in opioid-tolerant patients 2 years of age and older when a continuous, around-the-clock opioid analgesic is required for an extended period of time, and the patient cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.</p><p>Patients considered opioid-tolerant are those who are taking at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid for a week or longer.</p><p>&nbsp;</p><p><u>The initial dose of FENTANYL TRANSDERMAL SYSTEM </u>should be obtained or calculated from the conversion tables (see <strong>DOSAGE AND ADMINISTRATION</strong>), and must <strong>not </strong>be higher than that dose which is equivalent to the total dose of opioids the patient is receiving at the time of the switch to the patch.</p><p>&nbsp;</p><p>Because serious or life-threatening hypoventilation could occur, FENTANYL TRANSDERMAL SYSTEM should not be used in:</p><p>&middot; non-opioid-tolerant patients</p><p>&middot; the management of postoperative pain</p><p>&nbsp;</p><p><strong><u>Special Populations</u> </strong></p><p><strong>Pediatrics</strong></p><p>Used with caution as life-threatening respiratory depression has been reported in some pediatric patients receiving fentanyl transdermal system.</p><p>The use of FENTANYL TRANSDERMAL SYSTEM in children under 18 years of age is not recommended, as dosage requirements for the safe and efficacious use of FENTANYL TRANSDERMAL SYSTEM have not been established for this patient population. Life-threatening hypoventilation has been reported in some pediatric patients receiving fentanyl transdermal system.</p><p>&nbsp;</p><p><strong>Elderly and Debilitated Patients</strong></p><p>In elderly, cachectic, or debilitated patients, FENTANYL TRANSDERMAL SYSTEM may have altered pharmacokinetics due to poor fat stores, muscle wasting or altered clearance (see <strong>DOSAGE AND ADMINISTRATION). </strong>Therefore, it may be appropriate, according to clinical judgment, to initiate these patients on a lower FENTANYL TRANSDERMAL SYSTEM dose than that which the conversion tables recommend (see <strong>CONTRAINDICATIONS)</strong>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp;<u>General</u></strong></p><p><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>should</strong><strong> </strong><strong>only</strong><strong> </strong><strong>be</strong><strong> </strong><strong>prescribed</strong><strong> </strong><strong>by</strong><strong> </strong><strong>persons</strong><strong> </strong><strong>knowledgeable</strong><strong> </strong><strong>in</strong><strong> </strong><strong>the</strong><strong> </strong><strong>continuous</strong><strong> </strong><strong>administration</strong><strong> </strong><strong>of</strong><strong> </strong><strong>potent</strong><strong> </strong><strong>opioids,</strong><strong> </strong><strong>in</strong><strong> </strong><strong>the</strong><strong> </strong><strong>management</strong><strong> </strong><strong>of</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>receiving</strong><strong> </strong><strong>potent</strong><strong> </strong><strong>opioids</strong><strong> </strong><strong>for</strong><strong> </strong><strong>treatment</strong><strong> </strong><strong>of</strong><strong> </strong><strong>pain</strong><strong> </strong><strong>and</strong><strong> </strong><strong>in</strong><strong> </strong><strong>the</strong><strong> </strong><strong>detection</strong><strong> </strong><strong>and</strong><strong> </strong><strong>management</strong><strong> </strong><strong>of</strong><strong> </strong><strong>respiratory</strong><strong> </strong><strong>depression</strong><strong> including the use of opioid antagonists.</strong></p><p><strong>At</strong><strong> </strong><strong>the</strong><strong> </strong><strong>time</strong><strong> </strong><strong>of</strong><strong> </strong><strong>the</strong><strong> </strong><strong>switch</strong><strong> </strong><strong>to</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>from</strong><strong> </strong><strong>other</strong><strong> </strong><strong>opioids,</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>must</strong><strong> </strong><strong>be</strong><strong> </strong><strong>tolerant</strong><strong> </strong><strong>to</strong><strong> </strong><strong>opioid</strong><strong> </strong><strong>therapy</strong><strong> </strong><strong>of</strong><strong> </strong><strong>comparable</strong><strong> </strong><strong>potency</strong><strong> </strong><strong>to</strong><strong> </strong><strong>that</strong><strong> </strong><strong>of</strong><strong> </strong><strong>the</strong><strong> </strong><strong>intended</strong><strong> </strong><strong>initiating</strong><strong> </strong><strong>dose.</strong><strong> </strong><strong>Use</strong><strong> </strong><strong>of</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>in</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>who</strong><strong> </strong><strong>are</strong><strong> </strong><strong>non-opioid-</strong><strong> </strong><strong>tolerant,</strong><strong> </strong><strong>or</strong><strong> </strong><strong>insufficiently</strong><strong> </strong><strong>tolerant,</strong><strong> </strong><strong>may</strong><strong> </strong><strong>lead</strong><strong> </strong><strong>to</strong><strong> fatal respiratory depression.</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Dosing</u></strong><strong><u> </u></strong><strong><u>Considerations</u></strong></p><p>FENTANYL TRANSDERMAL SYSTEM doses must be individualized based upon the status of each patient and should be assessed at regular intervals after application. Proper optimization of doses scaled to the relief of the individual&#39;s pain should aim at the regular administration of the lowest dose of FENTANYL TRANSDERMAL SYSTEM which will achieve the overall treatment goal of satisfactory pain relief with acceptable side effects. Dosage of the drug must be individualized according to the response and tolerance of the patient. The most important factor to be considered in determining the appropriate dose is the extent of pre-existing opioid tolerance.</p><p>Reduced doses of FENTANYL TRANSDERMAL SYSTEM are suggested for the elderly and other groups discussed in <strong>WARNINGS</strong><strong> </strong><strong>AND</strong><strong> </strong><strong>PRECAUTIONS.</strong></p><p><strong>There has been no systematic evaluation of FENTANYL TRANSDERMAL SYSTEM as an initial opioid analgesic in the management of chronic pain. Most patients in the clinical trials were converted to fentanyl transdermal system from other opioid therapies on which inadequate to moderate pain control had been experienced prior to conversion.</strong></p><p><strong>Initiation</strong><strong> </strong><strong>of</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>in</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>who</strong><strong> </strong><strong>are</strong><strong> </strong><strong>opioid-naive</strong><strong> </strong><strong>is</strong><strong> </strong><strong>contraindicated</strong><strong> </strong><strong>at</strong><strong> </strong><strong>any</strong><strong> </strong><strong>dose</strong><strong> </strong><strong>(see</strong><strong> </strong><strong>CONTRAINDICATIONS).</strong><strong> </strong><strong>The</strong><strong> </strong><strong>initial</strong><strong> </strong><strong>dose</strong><strong> </strong><strong>of</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>should</strong><strong> </strong><strong>be</strong><strong> </strong><strong>obtained</strong><strong> </strong><strong>from</strong><strong> </strong><strong>the</strong><strong> </strong><strong>conversion</strong><strong> </strong><strong>tables</strong><strong> </strong><strong>in</strong><strong> </strong><strong>DOSAGE</strong><strong> </strong><strong>AND</strong><strong> </strong><strong>ADMINISTRATION,</strong><strong> </strong><strong>and</strong><strong> </strong><strong>must</strong><strong> </strong><strong><u>not</u></strong><strong><u> </u></strong><strong>be</strong><strong> </strong><strong>higher</strong><strong> </strong><strong>than</strong><strong> </strong><strong>that</strong><strong> </strong><strong>dose</strong><strong> </strong><strong>which</strong><strong> </strong><strong>is</strong><strong> </strong><strong>equivalent</strong><strong> </strong><strong>to</strong><strong> </strong><strong>the</strong><strong> </strong><strong>total</strong><strong> </strong><strong>dose</strong><strong> </strong><strong>of</strong><strong> </strong><strong>opioids</strong><strong> </strong><strong>the</strong><strong> </strong><strong>patient</strong><strong> </strong><strong>is</strong><strong> </strong><strong>receiving</strong><strong> </strong><strong>at</strong><strong> </strong><strong>the</strong><strong> </strong><strong>time</strong><strong> </strong><strong>of</strong><strong> </strong><strong>the</strong><strong> </strong><strong>switch</strong><strong> </strong><strong>to</strong><strong> </strong><strong>the</strong><strong> </strong><strong>patch.</strong><strong> </strong><strong>It</strong><strong> </strong><strong>may</strong><strong> </strong><strong>be</strong><strong> </strong><strong>appropriate,</strong><strong> </strong><strong>according</strong><strong> </strong><strong>to</strong><strong> </strong><strong>clinical</strong><strong> </strong><strong>judgment,</strong><strong> </strong><strong>to</strong><strong> </strong><strong>initiate</strong><strong> </strong><strong>some</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>on</strong><strong> </strong><strong>a lower FENTANYL TRANSDERMAL SYSTEM dose than that which the conversion tables recommend (see CONTRAINDICATIONS).</strong></p><p>Opioid analgesics may be only partially effective in relieving dysesthetic pain, postherpetic neuralgia, stabbing pains, activity-related pain and some forms of headache. That is not to say that patients with these types of pain should not be given an adequate trial of opioid analgesics, but it may be necessary to refer such patients at an early time to other forms of pain therapy.</p><p><strong>FENTANYL TRANSDERMAL SYSTEM has a high potential for abuse and diversion (see WARNINGS AND PRECAUTIONS).</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Concomitant</u></strong><strong><u> </u></strong><strong><u>Use</u></strong><strong><u> </u></strong><strong><u>of</u></strong><strong><u> </u></strong><strong><u>CYP3A4</u></strong><strong><u> </u></strong><strong><u>Inhibitors</u></strong></p><p>The concomitant use of fentanyl transdermal system with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazodone, verapamil, diltiazem, amiodarone, amprenavir, fosamprenavir, aprepitant, fluconazole, erythromycin and grapefruit juice) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Patients concomitantly exposed to fentanyl transdermal system and potent CYP3A4 inhibitors should be carefully monitored for an extended period of time and dosage adjustments should be made if warranted (see <strong>INTERACTION </strong><strong>WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION).</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Recommended Dose and Dosage Adjustment</u> </strong></p><p><strong>Pediatrics</strong></p><p>The use of FENTANYL TRANSDERMAL SYSTEM in children under 18 years of age is not recommended as dosage requirements for the safe and efficacious use of FENTANYL TRANSDERMAL SYSTEM have not been established for this patient population. Life-threatening hypoventilation has been reported in some pediatric patients receiving FENTANYL TRANSDERMAL SYSTEM.</p><p>&nbsp;</p><p><strong>Adults: Initial Dose Selection</strong></p><p>In selecting an initial FENTANYL TRANSDERMAL SYSTEM dose, attention should be given to 1) the daily dose, potency, and characteristics of the opioid the patient has been taking previously (e.g. whether it is a pure agonist or mixed agonist-antagonist), 2) the reliability of the relative potency estimates used to calculate the FENTANYL TRANSDERMAL SYSTEM dose needed (potency estimates may vary with the route of administration), 3) the degree of opioid tolerance, and 4) the general condition and medical status of the patient.</p><p>&nbsp;</p><p>At the time of the switch to FENTANYL TRANSDERMAL SYSTEM, patients must be tolerant to opioid therapy of comparable potency to that of the intended initiating dose. It may be appropriate, according to clinical judgment, to initiate some patients on a lower FENTANYL TRANSDERMAL SYSTEM dose than that which the conversion tables recommend. Overestimating the FENTANYL TRANSDERMAL SYSTEM dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Due to the mean elimination half-life of 17 hours of fentanyl, patients who are thought to have had a serious adverse event, including overdose, will require monitoring and treatment for at least 24 hours or until the adverse event has subsided.</p><p>&nbsp;</p><p><strong>Parenteral/Oral/Equianalgesic Potency Conversion</strong></p><p>To convert adult patients from oral or parenteral opioids to FENTANYL TRANSDERMAL SYSTEM, use Table 1.1.</p><p>&nbsp;</p><p>Alternatively, for adult patients taking opioids or doses not listed in Table 1.1, use the following methodology:</p><p>1. Calculate the previous 24-hour analgesic requirement expressed in morphine equivalents.</p><p>2. Use Table 1.2 to convert this equianalgesic morphine dose to the recommended initial FENTANYL TRANSDERMAL SYSTEM dose. <strong>This</strong><strong> </strong><strong>conversion</strong><strong> </strong><strong>recommendation</strong><strong> </strong><strong>is</strong><strong> </strong><strong>intentionally</strong><strong> </strong><strong>conservative</strong><strong> </strong><strong>to</strong><strong> </strong><strong>minimize</strong><strong> </strong><strong>the</strong><strong> </strong><strong>potential</strong><strong> </strong><strong>for</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>overdosage.</strong></p><p>For delivery rates in excess of 100 mcg/h, multiple systems may be applied.</p><p>Because of the gradual increase in serum fentanyl concentration over the first 24 hours following initial system application, the initial evaluation of the maximum analgesic effect of FENTANYL TRANSDERMAL SYSTEM cannot be made before 24 hours of wearing. Patients should use short- acting analgesics after the initial dose application as needed until analgesic efficacy with FENTANYL TRANSDERMAL SYSTEM is attained.</p><p>&nbsp;</p><p><strong>Initial Dose Selection in Elderly, Cachectic, or Debilitated Patients</strong></p><p>In patients from these populations, fentanyl transdermal system may have altered pharmacokinetics due to poor fat stores, muscle wasting or altered clearance. Therefore, it may be appropriate, according to clinical judgment, to initiate these patients on FENTANYL TRANSDERMAL SYSTEM at a dose level lower than that which the conversion tables recommend (see <strong>CONTRAINDICATIONS). </strong>As with all FENTANYL TRANSDERMAL SYSTEM patients, they should be carefully monitored for pain levels and adverse events, particularly hypoventilation.</p><p>&nbsp;</p><p><strong><u>Dose Adjustment</u></strong></p><p>Dose titration is the key to success with opioid analgesic therapy. The recommended initial FENTANYL TRANSDERMAL SYSTEM dose based upon the daily morphine dose is conservative, and 50% of patients are likely to require a dose increase after initial application of FENTANYL TRANSDERMAL SYSTEM. If analgesia is insufficient after the initial application, the first dosage increase should occur three days after application, while all subsequent dosage increases should occur six days following the previous application.</p><p>&nbsp;</p><p><strong><u>Initial Dosage Increase: </u>The initial FENTANYL TRANSDERMAL SYSTEM dosage may be increased after 3 days based on the daily dose of supplemental analgesics required by the patients in the second or third day of the initial application.</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>All</u></strong><strong><u> </u></strong><strong><u>Other</u></strong><strong><u> Dosage</u></strong><strong><u> </u></strong><strong><u>Increases</u></strong><strong>:</strong><strong> </strong><strong>Physicians</strong><strong> </strong><strong>are</strong><strong> </strong><strong>advised</strong><strong> </strong><strong>that</strong><strong> </strong><strong>it</strong><strong> </strong><strong>may</strong><strong> </strong><strong>take</strong><strong> </strong><strong>up</strong><strong> </strong><strong>to</strong><strong> </strong><strong>6 days after increasing the dose of FENTANYL TRANSDERMAL SYSTEM for the patient to reach equilibrium on the new dose. Therefore, patients should wear a higher dose through two applications before any further increase in dosage is made on the basis of the average daily use of a supplemental analgesic.</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Titration</u></strong><strong><u> </u></strong><strong><u>Dose</u></strong><strong><u> </u></strong><strong><u>Increment</u></strong><strong>:</strong><strong> </strong><strong>Dosage</strong><strong> </strong><strong>of</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>must</strong><strong> </strong><strong>be</strong><strong> </strong><strong>individualized</strong><strong> </strong><strong>according</strong><strong> </strong><strong>to</strong><strong> </strong><strong>the</strong><strong> </strong><strong>pain</strong><strong> </strong><strong>relief</strong><strong> </strong><strong>and</strong><strong> </strong><strong>tolerance</strong><strong> </strong><strong>of</strong><strong> </strong><strong>the</strong><strong> </strong><strong>patient.</strong><strong> </strong><strong>Appropriate</strong><strong> </strong><strong>dosage</strong><strong> </strong><strong>increments</strong><strong> </strong><strong>should</strong><strong> </strong><strong>be</strong><strong> </strong><strong>based</strong><strong> </strong><strong>on</strong><strong> </strong><strong>the</strong><strong> </strong><strong>daily</strong><strong> </strong><strong>dose</strong><strong> </strong><strong>of</strong><strong> </strong><strong>supplementary</strong><strong> </strong><strong>opioids.</strong><strong> </strong><strong>Some</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>may</strong><strong> </strong><strong>continue</strong><strong> </strong><strong>to</strong><strong> </strong><strong>require</strong><strong> </strong><strong>periodic</strong><strong> </strong><strong>supplemental</strong><strong> </strong><strong>doses</strong><strong> </strong><strong>of</strong><strong> </strong><strong>short-acting</strong><strong> </strong><strong>analgesic</strong><strong> </strong><strong>for</strong><strong> </strong><strong>&lsquo;breakthrough&rsquo;</strong><strong> </strong><strong>pain.</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Maintenance</u></strong></p><p>The majority of patients are adequately maintained with FENTANYL TRANSDERMAL SYSTEM administered every 72 hours. A small number of patients may not achieve adequate analgesia using this dosing interval and may require systems to be applied every 48 hours rather than every 72 hours. If breakthrough pain repeatedly occurs at the end of the dosing interval, it is generally an indication for a dosage increase rather than more frequent administration. An increase in the FENTANYL TRANSDERMAL SYSTEM dose should be considered before changing dosing intervals in order to maintain patients on a 72-hour regimen.</p><p>Some patients may require additional or alternative methods of opioid administration when the FENTANYL TRANSDERMAL SYSTEM dose exceeds 300 mcg/h.</p><p>&nbsp;</p><p><strong><u>Decreased Dosing or Discontinuation of FENTANYL TRANSDERMAL SYSTEM</u></strong></p><p>Following the successful relief of severe pain, periodic attempts should be made to reduce the opioid dose. Lower doses or complete discontinuation of the opioid analgesic may become feasible due to physiological change or improved mental state of the patient.</p><p>Opioid withdrawal symptoms, such as nausea, vomiting, diarrhea, anxiety and shivering, are possible in some patients after conversion or dose decrease.</p><p>For patients requiring discontinuation of opioids, a gradual downward titration is recommended since it is not known at what dose level the opioid may be discontinued without producing the signs and symptoms of abrupt withdrawal (see <strong><u>Dose Adjustment</u>, Titration Dose Increment</strong>)</p><p><strong>For all downward titration, it is important to note that it takes 17 hours or more for the fentanyl serum concentration to fall by 50% after system removal.</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Safe</u></strong><strong><u> </u></strong><strong><u>Use</u></strong><strong><u> </u></strong><strong><u>of</u></strong><strong><u> Tables</u></strong><strong><u> </u></strong><strong><u>1.1</u></strong><strong><u> and</u></strong><strong><u> </u></strong><strong><u>1.2</u></strong></p><p>To convert patients to another opioid, remove FENTANYL TRANSDERMAL SYSTEM and titrate the dose of the new analgesic, based upon the patient&#39;s report of pain, until adequate analgesia has been attained.</p><p>&nbsp;</p><p><strong>Tables</strong><strong> </strong><strong>1.1</strong><strong> </strong><strong>and</strong><strong> </strong><strong>1.2</strong><strong> </strong><strong>should</strong><strong> </strong><strong>not</strong><strong> </strong><strong>be</strong><strong> </strong><strong>used</strong><strong> </strong><strong>to</strong><strong> </strong><strong>convert</strong><strong> </strong><strong>from</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>to</strong><strong> </strong><strong>other</strong><strong> </strong><strong>opioid</strong><strong> </strong><strong>therapies.</strong><strong> </strong>Because the conversion to fentanyl transdermal system is conservative, use of Tables 1.1 and 1.2 for conversion to other analgesic therapies can overestimate the dose of the new agent. Overdosage of the new analgesic agent is possible.</p><p>&nbsp;</p><p><strong>Table 1.1<sup>1</sup>&nbsp;Dose Conversion Guidelines</strong></p><p><strong>Dose</strong><strong> </strong><strong>Conversion</strong><strong> </strong><strong>Guidelines</strong><strong> </strong><strong>are</strong><strong> </strong><strong>Unidirectional</strong><strong> </strong><strong>and</strong><strong> </strong><strong>for</strong><strong> </strong><strong>Chronic</strong><strong> </strong><strong>use.</strong></p><p><strong>Use</strong><strong> </strong><strong>this</strong><strong> </strong><strong>table</strong><strong> </strong><strong>to</strong><strong> </strong><strong>convert</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>from</strong><strong> </strong><strong>the</strong><strong> </strong><strong>Current</strong><strong> </strong><strong>Analgesic</strong><strong> </strong><strong>ONLY</strong><strong> </strong><strong>to</strong><strong> </strong><strong>Fentanyl</strong><strong> </strong><strong>Transdermal</strong><strong> </strong><strong>System.</strong><strong> </strong><strong>Do</strong><strong> </strong><strong>NOT</strong><strong> </strong><strong>use</strong><strong> </strong><strong>this</strong><strong> </strong><strong>table</strong><strong> </strong><strong>to</strong><strong> </strong><strong>convert</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>from</strong><strong> </strong><strong>Fentanyl</strong><strong> </strong><strong>Transdermal</strong><strong> </strong><strong>System</strong><strong> </strong><strong>to</strong><strong> </strong><strong>other</strong><strong> </strong><strong>opiods;</strong><strong> </strong><strong>doing&nbsp;</strong><strong>so may result in overdose and toxicity</strong></p><p><!--[if gte vml 1]><v:group
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:78pt;margin-top:32.7pt;width:472.95pt;height:.1pt;z-index:-42112;
 mso-position-horizontal-relative:page' coordorigin="1560,654" coordsize="9459,2">
 <v:shape id="_x0000_s1027" style='position:absolute;left:1560;top:654;width:9459;
  height:2' coordorigin="1560,654" coordsize="9459,0" path="m1560,654r9458,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="633" height="2" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Current</strong><strong> </strong><strong>Analgesic&nbsp;</strong></p></td><td rowspan="1" colspan="4"><p><strong>Daily Dosage (mg/d)</strong></p></td></tr><tr><td><p>Oral morphine</p></td><td><p>60-134</p></td><td><p>135-224</p></td><td><p>225-314</p></td><td><p>315-404</p></td></tr><tr><td><p>IM/IV morphine(based on a 1:3 IM:PO ratio)</p></td><td><p>20-44</p></td><td><p>45-75</p></td><td><p>NA<sup>2</sup></p></td><td><p>NA<sup>2</sup></p></td></tr><tr><td><p>Oral oxycodone</p></td><td><p>30-66</p></td><td><p>67-112</p></td><td><p>113-157</p></td><td><p>158-202</p></td></tr><tr><td><p>Oral codeine</p></td><td><p>150-447</p></td><td><p>448-747</p></td><td><p>748-1047</p></td><td><p>1048-1347</p></td></tr><tr><td><p>Oral hydromorphone</p></td><td><p>8-16</p></td><td><p>17-28</p></td><td><p>29-39</p></td><td><p>40-51</p></td></tr><tr><td><p>IV hydromorphine<sup>3</sup></p></td><td><p>4.0-8.4</p></td><td><p>8.5-14.4</p></td><td><p>14.5-19.5</p></td><td><p>19.6-25.5</p></td></tr><tr><td><p><strong>Recommended</strong><strong> </strong><strong>Fentanyl</strong><strong> </strong><strong>transdermal</strong><strong> </strong><strong>system</strong><strong> </strong><strong>dose</strong></p></td><td><p><strong>25mcg/h</strong></p></td><td><p><strong>50mcg/h&nbsp;</strong></p></td><td><p><strong>75mcg/h</strong></p></td><td><p><strong>100mcg/h</strong></p></td></tr></tbody></table><p>&nbsp;<strong><sup>1</sup></strong><strong>Table<strong> </strong>1.1</strong><strong> </strong><strong>should</strong><strong> </strong><strong>not</strong><strong> </strong><strong>be</strong><strong> </strong><strong>used</strong><strong> </strong><strong>to</strong><strong> </strong><strong>convert</strong><strong> </strong><strong>from</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>to</strong><strong> </strong><strong>other</strong><strong> </strong><strong>therapies</strong><strong> </strong><strong>because</strong><strong> </strong><strong>this</strong><strong> </strong><strong>conversion</strong><strong> </strong><strong>to</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>is</strong><strong> </strong><strong>conservative.</strong><strong> </strong><strong>Use</strong><strong> </strong><strong>of</strong><strong> </strong><strong>Table</strong><strong> </strong><strong>1.1</strong><strong> </strong><strong>for</strong><strong> </strong><strong>conversion</strong><strong> </strong><strong>to</strong><strong> </strong><strong>other</strong><strong> </strong><strong>analgesic</strong><strong> </strong><strong>therapies</strong><strong> </strong><strong>can</strong><strong> </strong><strong>overestimate</strong><strong> </strong><strong>the</strong><strong> </strong><strong>dose</strong><strong> </strong><strong>of</strong><strong> </strong><strong>the</strong><strong> </strong><strong>new</strong><strong> </strong><strong>agent.</strong><strong> </strong><strong>Overdosage</strong><strong> </strong><strong>of</strong><strong> </strong><strong>the</strong><strong> </strong><strong>new</strong><strong> </strong><strong>analgesic</strong><strong> </strong><strong>agent</strong><strong> </strong><strong>is</strong><strong> </strong><strong>possible</strong><strong> </strong><strong>(see</strong><strong> </strong><strong>DOSAGE</strong><strong> </strong><strong>AND ADMINISTRATION, <u>Safe Use of Tables 1.1 and</u> <u>1.2</u>).</strong></p><p><strong><sup>2</sup>NA reflects insufficient data available for guidance. Prescribers should make these conversions very carefully and conservatively.</strong></p><p><strong><sup>3</sup></strong>The conversion ratio of parenteral hydromorphone to oral hydromorphone of 1:2 is based on clinical experience in patients with chronic pain. Reference: Parenteral Drug Therapy Manual, Vancouver General Hospital, Pharmaceutical Sciences Clinical Services.</p><p>&nbsp;</p><p><strong>Table</strong><strong> </strong><strong>1.2:</strong><strong> </strong><strong>Recommended</strong><strong> </strong><strong>initial</strong><strong> </strong><strong>Fentanyl</strong><strong> </strong><strong>Transdermal</strong><strong> </strong><strong>System</strong><strong> </strong><strong>Dose</strong><strong> </strong><strong>Based Upon Daily Oral Morphine Dose*</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Oral</strong><strong> </strong><strong>24-hour</strong><strong> </strong><strong>morphine</strong><strong> </strong><strong>(mg/day)</strong></p></td><td><p><strong>Fentanyl</strong><strong> </strong><strong>Transdermal</strong><strong> </strong><strong>System</strong><strong> </strong><strong>(mcg/h)</strong></p></td></tr><tr><td><p>60-134</p></td><td><p>25</p></td></tr><tr><td><p>135-224</p></td><td><p>50</p></td></tr><tr><td><p>225-314</p></td><td><p>75</p></td></tr><tr><td><p>315-404</p></td><td><p>100</p></td></tr><tr><td><p>405-494</p></td><td><p>125</p></td></tr><tr><td><p>495-584</p></td><td><p>150</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>585-674</p></td><td><p>175</p></td></tr><tr><td><p>675-764</p></td><td><p>200</p></td></tr><tr><td><p>765-854</p></td><td><p>225</p></td></tr><tr><td><p>855-944</p></td><td><p>250</p></td></tr><tr><td><p>945-1034</p></td><td><p>275</p></td></tr><tr><td><p>1035-1124</p></td><td><p>300</p></td></tr></tbody></table><p>*In clinical trials these ranges of daily oral morphine doses were used as a basis for conversion to fentanyl transdermal system. See <strong><u>Recommended</u></strong><strong><u> Dose and Dosage Adjustment</u>, Dose Adjustment.</strong></p><p>&nbsp;</p><p><strong><u>Administration</u></strong></p><p><strong>Application</strong><strong> </strong><strong>of</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong></p><p>FENTANYL TRANSDERMAL SYSTEM should be applied to non-irritated and non-irradiated skin on a flat surface such as the chest, back, flank, or upper arm. Hair at the application site should be clipped (not shaved) prior to application. If the site of FENTANYL TRANSDERMAL SYSTEM application must be cleansed prior to application of the system, do so with clear water. Do not use soaps, oils, lotions, alcohol, or any other agents that may irritate the skin or alter its characteristics. Allow the skin to dry completely prior to system application.</p><p>FENTANYL TRANSDERMAL SYSTEM should be applied immediately upon removal from the sealed package. The system should not be altered, e.g., cut, in any way prior to its application. The transdermal system should be pressed firmly in place with the palm of the hand for 30 seconds, making sure the contact is complete, especially around the edges.</p><p>Each FENTANYL TRANSDERMAL SYSTEM may be worn continuously for 72 hours. A new system should be applied on a different skin site after removal of the previous transdermal system.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Because serious or life-threatening hypoventilation could occur, FENTANYL TRANSDERMAL SYSTEM is contraindicated in:
1) patients with acute or perioperative pain, especially use in out-patient or day surgeries (see WARNINGS AND PRECAUTIONS, Perioperative Considerations);
2) patients with mild, intermittent or short duration pain that can otherwise be managed;
3) opioid-naive patients, at any dose;
4) situations of significant respiratory depression, especially in unmonitored settings where there is a lack of resuscitative equipment; and
5) patients who have acute or severe bronchial asthma.

Because serious or life-threatening hypoventilation could occur, the maximum initiation dose  of FENTANYL TRANSDERMAL SYSTEM should not be higher than that equivalent to the total dose of opioids the patient is receiving at the time of the switch (see conversion tables in DOSAGE AND ADMINISTRATION).

FENTANYL TRANSDERMAL SYSTEM is contraindicated in patients who have or are suspected of having paralytic ileus.
 
FENTANYL TRANSDERMAL SYSTEM is contraindicated in patients with known hypersensitivity to fentanyl or to the adhesives present in the system.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>General</u></strong></p><p><strong>Use</strong><strong> </strong><strong>in</strong><strong> </strong><strong>non-opioid-tolerant</strong><strong> </strong><strong>patients,</strong><strong> </strong><strong>or</strong><strong> </strong><strong>use</strong><strong> </strong><strong>of</strong><strong> </strong><strong>an</strong><strong> </strong><strong>initiating</strong><strong> </strong><strong>dose</strong><strong> </strong><strong>which</strong><strong> </strong><strong>is</strong><strong> </strong><strong>higher</strong><strong> </strong><strong>than</strong><strong> </strong><strong>the</strong><strong> </strong><strong>opioid equivalent<strong> </strong>to</strong><strong> </strong><strong>which</strong><strong> </strong><strong>the</strong><strong> </strong><strong>patient</strong><strong> </strong><strong>is</strong><strong> </strong><strong>tolerant</strong><strong> </strong><strong>at</strong><strong> </strong><strong>the</strong><strong> </strong><strong>time</strong><strong> </strong><strong>of</strong><strong> </strong><strong>the</strong><strong> </strong><strong>switch,</strong><strong> </strong><strong>may</strong><strong> </strong><strong>lead</strong><strong> </strong><strong>to</strong><strong> </strong><strong>fatal</strong><strong> </strong><strong>respiratory</strong><strong> depression.</strong></p><p><strong><u>The</u></strong><strong><u> </u></strong><strong><u>following</u></strong><strong><u> </u></strong><strong><u>contraindications</u></strong><strong><u> </u></strong><strong><u>reduce</u></strong><strong><u> </u></strong><strong><u>the</u></strong><strong><u> </u></strong><strong><u>potential</u></strong><strong><u> </u></strong><strong><u>risk</u></strong><strong><u> </u></strong><strong><u>of</u></strong><strong><u> </u></strong><strong><u>serious</u></strong><strong><u> </u></strong><strong><u>or</u></strong><strong><u> </u></strong><strong><u>life-threatening,</u></strong><strong> </strong><strong><u>hypoventilation</u></strong><strong>:</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>should</strong><strong> </strong><strong>not</strong><strong> </strong><strong>be</strong><strong> </strong><strong>used</strong><strong> </strong><strong>in</strong><strong> </strong><strong>the</strong><strong> </strong><strong>management</strong><strong> </strong><strong>of</strong><strong> </strong><strong>acute</strong><strong> </strong><strong>or</strong><strong> </strong><strong>postoperative</strong><strong> </strong><strong>pain</strong><strong> </strong><strong>since</strong><strong> </strong><strong>there</strong><strong> </strong><strong>is</strong><strong> </strong><strong>no</strong><strong> </strong><strong>opportunity</strong><strong> </strong><strong>for</strong><strong> </strong><strong>dose</strong><strong> </strong><strong>titration</strong><strong> </strong><strong>during</strong><strong> </strong><strong>short-term</strong><strong> </strong><strong>use</strong><strong> </strong><strong>and</strong><strong> </strong><strong>serious</strong><strong> </strong><strong>or</strong><strong> </strong><strong>life-threatening</strong><strong> </strong><strong>hypoventilation</strong><strong> </strong><strong>could</strong><strong> </strong><strong>result.</strong><strong> </strong><strong>Similarly,</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>should</strong><strong> </strong><strong>not</strong><strong> </strong><strong>be</strong><strong> </strong><strong>administered</strong><strong> </strong><strong>to</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>who</strong><strong> </strong><strong>do</strong><strong> </strong><strong>not</strong><strong> </strong><strong>have</strong><strong> </strong><strong>some</strong><strong> </strong><strong>degree</strong><strong> </strong><strong>of</strong><strong> </strong><strong>tolerance</strong><strong> </strong><strong>to</strong><strong> </strong><strong>opioid-induced</strong><strong> </strong><strong>side</strong><strong> </strong><strong>effects.</strong><strong> &nbsp;FENTANYL TRANSDERMAL SYSTEM should ONLY be prescribed to patients who require continuous opioids for pain management, and who are tolerant to at least the morphine equivalent of the lowest initiating FENTANYL TRANSDERMAL SYSTEM dose.</strong></p><p><strong>The</strong><strong> </strong><strong>initial</strong><strong> </strong><strong>dose</strong><strong> </strong><strong>of</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>should</strong><strong> </strong><strong>be</strong><strong> </strong><strong>obtained</strong><strong> </strong><strong>from</strong><strong> </strong><strong>the</strong><strong> </strong><strong>conversion</strong><strong> </strong><strong>tables</strong><strong> </strong><strong>in</strong><strong> </strong><strong>DOSAGE</strong><strong> </strong><strong>AND</strong><strong> </strong><strong>ADMINISTRATION,</strong><strong> </strong><strong>and</strong><strong> </strong><strong>must</strong><strong> </strong><strong><u>not </u></strong><strong>be</strong><strong> </strong><strong>higher</strong><strong> </strong><strong>than</strong><strong> </strong><strong>that</strong><strong> </strong><strong>dose</strong><strong> </strong><strong>which</strong><strong> </strong><strong>is</strong><strong> </strong><strong>equivalent</strong><strong> </strong><strong>to</strong><strong> </strong><strong>the</strong><strong> </strong><strong>total</strong><strong> </strong><strong>dose</strong><strong> </strong><strong>of</strong><strong> </strong><strong>opioids</strong><strong> </strong><strong>the</strong><strong> </strong><strong>patient</strong><strong> </strong><strong>is</strong><strong> </strong><strong>receiving</strong><strong> </strong><strong>at</strong><strong> </strong><strong>the</strong><strong> </strong><strong>time</strong><strong> </strong><strong>of</strong><strong> </strong><strong>the</strong><strong> </strong><strong>switch</strong><strong> </strong><strong>to</strong><strong> </strong><strong>the</strong><strong> </strong><strong>patch.</strong><strong> </strong><strong>It</strong><strong> </strong><strong>may</strong><strong> </strong><strong>be</strong><strong> </strong><strong>appropriate,</strong><strong> </strong><strong>according</strong><strong> </strong><strong>to</strong><strong> </strong><strong>clinical</strong><strong> </strong><strong>judgment,</strong><strong> </strong><strong>to</strong><strong> </strong><strong>initiate</strong><strong> </strong><strong>some</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>on</strong><strong> </strong><strong>a lower FENTANYL TRANSDERMAL SYSTEM dose than that which the conversion tables recommend. Opioid-naive patients should <u>not </u>be given FENTANYL TRANSDERMAL SYSTEM at any dose (see CONTRAINDICATION).</strong></p><p><strong>The</strong><strong> </strong><strong>use</strong><strong> </strong><strong>of</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>in</strong><strong> </strong><strong>children</strong><strong> </strong><strong>under</strong><strong> </strong><strong>18</strong><strong> </strong><strong>years</strong><strong> </strong><strong>of</strong><strong> </strong><strong>age</strong><strong> </strong><strong>is</strong><strong> </strong><strong>not</strong><strong> </strong><strong>recommended</strong><strong> </strong><strong>as</strong><strong> </strong><strong>dosage</strong><strong> </strong><strong>requirements</strong><strong> </strong><strong>for</strong><strong> </strong><strong>the</strong><strong> </strong><strong>safe</strong><strong> </strong><strong>and</strong><strong> </strong><strong>efficacious</strong><strong> </strong><strong>use</strong><strong> </strong><strong>of</strong><strong> </strong><strong>fentanyl</strong><strong> </strong><strong>transdermal</strong><strong> </strong><strong>system</strong><strong> </strong><strong>have</strong><strong> </strong><strong>not</strong><strong> </strong><strong>been</strong><strong> </strong><strong>established</strong><strong> </strong><strong>for</strong><strong> </strong><strong>this</strong><strong> </strong><strong>patient</strong><strong> </strong><strong>population.</strong><strong> </strong><strong>Life-threatening</strong><strong> </strong><strong>hypoventilation</strong><strong> </strong><strong>has</strong><strong> </strong><strong>been</strong><strong> </strong><strong>reported</strong><strong> </strong><strong>in</strong><strong> </strong><strong>some</strong><strong> </strong><strong>pediatric</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>receiving</strong><strong> </strong><strong>fentanyl</strong><strong> </strong><strong>transdermal</strong><strong> </strong><strong>system.</strong></p><p><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>should</strong><strong> </strong><strong>only</strong><strong> </strong><strong>be</strong><strong> </strong><strong>prescribed</strong><strong> </strong><strong>by</strong><strong> </strong><strong>persons</strong><strong> </strong><strong>knowledgeable</strong><strong> </strong><strong>in</strong><strong> </strong><strong>the</strong><strong> </strong><strong>continuous</strong><strong> </strong><strong>administration</strong><strong> </strong><strong>of</strong><strong> </strong><strong>potent</strong><strong> </strong><strong>opioids,</strong><strong> </strong><strong>in</strong><strong> </strong><strong>the</strong><strong> </strong><strong>management</strong><strong> </strong><strong>of</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>receiving</strong><strong> </strong><strong>potent</strong><strong> </strong><strong>opioids</strong><strong> </strong><strong>for</strong><strong> </strong><strong>treatment</strong><strong> </strong><strong>of</strong><strong> </strong><strong>pain</strong><strong> </strong><strong>and</strong><strong> </strong><strong>in</strong><strong> </strong><strong>the</strong><strong> </strong><strong>detection</strong><strong> </strong><strong>and</strong><strong> </strong><strong>management</strong><strong> </strong><strong>of</strong><strong> </strong><strong>respiratory</strong><strong> </strong><strong>depression</strong><strong> including the use of opioid antagonists.</strong></p><p><strong>Since</strong><strong> </strong><strong>serum</strong><strong> </strong><strong>fentanyl</strong><strong> </strong><strong>concentrations</strong><strong> </strong><strong>decline</strong><strong> </strong><strong>gradually</strong><strong> </strong><strong>after</strong><strong> </strong><strong>system</strong><strong> </strong><strong>removal,</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>who</strong><strong> </strong><strong>have</strong><strong> </strong><strong>experienced</strong><strong> </strong><strong>serious</strong><strong> </strong><strong>adverse</strong><strong> </strong><strong>events</strong><strong> </strong><strong>should</strong><strong> </strong><strong>be</strong><strong> </strong><strong>monitored</strong><strong> </strong><strong>for</strong><strong> </strong><strong>at</strong><strong> </strong><strong>least</strong><strong> </strong><strong>24</strong><strong> </strong><strong>hours</strong><strong> </strong><strong>after</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>removal</strong><strong> </strong><strong>or</strong><strong> </strong><strong>until</strong><strong> </strong><strong>the</strong><strong> </strong><strong>adverse</strong><strong> </strong><strong>reaction</strong><strong> </strong><strong>has</strong><strong> </strong><strong>subsided.</strong></p><p><strong>As</strong><strong> </strong><strong>with</strong><strong> </strong><strong>other</strong><strong> </strong><strong>CNS</strong><strong> </strong><strong>depressants,</strong><strong> </strong><strong>patients</strong><strong> </strong><strong>who</strong><strong> </strong><strong>have</strong><strong> </strong><strong>received</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>should</strong><strong> </strong><strong>be</strong><strong> </strong><strong>closely</strong><strong> </strong><strong>monitored</strong><strong> </strong><strong>especially</strong><strong> </strong><strong>for</strong><strong> </strong><strong>signs</strong><strong> </strong><strong>of</strong><strong> </strong><strong>respiratory</strong><strong> </strong><strong>depression</strong><strong> </strong><strong>until</strong><strong> </strong><strong>a stable maintenance dose is reached.</strong></p><p><strong>Due</strong><strong> </strong><strong>to</strong><strong> </strong><strong>the</strong><strong> </strong><strong>formation</strong><strong> </strong><strong>of</strong><strong> </strong><strong>a subcutaneous depot of fentanyl, not only does continued exposure occur<strong> </strong>after<strong> </strong>system</strong><strong> </strong><strong>removal</strong><strong> </strong><strong>but,</strong><strong> </strong><strong>in</strong><strong> </strong><strong>the</strong><strong> </strong><strong>case</strong><strong> </strong><strong>of</strong><strong> </strong><strong>removal</strong><strong> </strong><strong>prior</strong><strong> </strong><strong>to</strong><strong> </strong><strong>attainment</strong><strong> </strong><strong>of</strong><strong> </strong><strong>peak</strong><strong> </strong><strong>fentanyl</strong><strong> </strong><strong>exposure,</strong><strong> </strong><strong>fentanyl</strong><strong> </strong><strong>plasma</strong><strong> </strong><strong>levels</strong><strong> </strong><strong>may</strong><strong> </strong><strong>in</strong><strong> </strong><strong>fact</strong><strong> </strong><strong>continue</strong><strong> </strong><strong>to</strong><strong> </strong><strong>increase</strong><strong> </strong><strong>after</strong><strong> </strong><strong>removal</strong><strong> of FENTANYL TRANSDERMAL SYSTEM patches.</strong></p><p><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>patches</strong><strong> </strong><strong>are</strong><strong> </strong><strong>intended</strong><strong> </strong><strong>for</strong><strong> </strong><strong>transdermal</strong><strong> </strong><strong>use</strong><strong> </strong><strong>on</strong><strong> </strong><strong>intact</strong><strong> </strong><strong>skin</strong><strong> </strong><strong>only;</strong><strong> </strong><strong>use</strong><strong> </strong><strong>on</strong><strong> </strong><strong>compromised</strong><strong> </strong><strong>skin</strong><strong> </strong><strong>can</strong><strong> </strong><strong>lead</strong><strong> </strong><strong>to</strong><strong> </strong><strong>increased</strong><strong> </strong><strong>exposure</strong><strong> </strong><strong>to</strong><strong> </strong><strong>fentanyl.</strong></p><p><strong>Placing</strong><strong> </strong><strong>FENTANYL</strong><strong> </strong><strong>TRANSDERMAL</strong><strong> </strong><strong>SYSTEM</strong><strong> </strong><strong>in</strong><strong> </strong><strong>the</strong><strong> </strong><strong>mouth,</strong><strong> </strong><strong>chewing</strong><strong> </strong><strong>it,</strong><strong> </strong><strong>swallowing</strong><strong> </strong><strong>it,</strong><strong> </strong><strong>or</strong><strong> </strong><strong>using</strong><strong> </strong><strong>it</strong><strong> </strong><strong>in</strong><strong> </strong><strong>any</strong><strong> </strong><strong>ways</strong><strong> </strong><strong>other</strong><strong> </strong><strong>than</strong><strong> </strong><strong>indicated</strong><strong> </strong><strong>may</strong><strong> </strong><strong>cause</strong><strong> </strong><strong>choking</strong><strong> </strong><strong>or</strong><strong> </strong><strong>overdose</strong><strong> </strong><strong>that could result in death.</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Risk</u></strong><strong><u> </u></strong><strong><u>of</u></strong><strong><u> </u></strong><strong><u>Unintentional</u></strong><strong><u> </u></strong><strong><u>Increase</u></strong><strong><u> </u></strong><strong><u>in</u></strong><strong><u> </u></strong><strong><u>Drug</u></strong><strong><u> </u></strong><strong><u>Exposure</u></strong></p><p><strong>Patients</strong><strong> </strong><strong>with</strong><strong> </strong><strong>Fever:</strong><strong> </strong>Serum fentanyl concentrations could theoretically increase by approximately one-third for patients with a body temperature of 40&deg;C (104&deg;F) due to temperature-dependent increases in fentanyl release from the system and increased skin permeability. Patients who develop fever should be monitored for opioid side effects and have their FENTANYL TRANSDERMAL SYSTEM dose adjusted if necessary.</p><p>&nbsp;</p><p><strong>External</strong><strong> </strong><strong>Heat</strong><strong> </strong><strong>Sources:</strong><strong> </strong><strong>There</strong><strong> </strong><strong>is</strong><strong> </strong><strong>a potential for temperature-dependent increases in fentanyl released from the system resulting in possible overdose and death. A clinical pharmacology trial conducted in healthy adult subjects has shown that the application of heat over the fentanyl transdermal system increased mean fentanyl AUC values by 120% and mean C</strong><strong>max</strong><strong>&nbsp;</strong><strong>values</strong><strong> </strong><strong>by</strong><strong> </strong><strong>61%</strong>. All patients should be advised to avoid exposing the FENTANYL TRANSDERMAL SYSTEM application site to direct external heat sources, such as heating pads, electric blankets, heated water beds, heat lamps, hot water bottles, saunas and hot whirlpool spa baths, intensive sunbathing, etc.</p><p>&nbsp;</p><p><strong><u>Accidental Exposure to FENTANYL TRANSDERMAL SYSTEM</u></strong></p><p>Serious medical consequences, including death, have occurred when people were accidentally exposed to fentanyl transdermal system. Examples of accidental exposure include transfer of a fentanyl transdermal system patch while hugging, sharing a bed, or moving a patient.</p><p>&nbsp;</p><p><strong><u>Disposal of FENTANYL TRANSDERMAL SYSTEM</u></strong></p><p>FENTANYL TRANSDERMAL SYSTEM should be kept out of the reach of children before and after use.</p><p>Used systems should be folded so that the adhesive side of the system adheres to itself, then flushed down the toilet immediately upon removal. If the drug adhesive layer accidentally contacts the skin, the area should be washed with clear water. Patients should dispose of any systems remaining from a prescription as soon as they are no longer needed. Unused systems should be removed from their pouch, folded so that the adhesive side of the system adheres to itself, then flushed down the toilet (see <strong>DOSAGE AND ADMINISTRATION </strong>and <strong>SPECIAL HANDLING INSTRUCTIONS).</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Cardiovascular</u></strong></p><p>Intravenous fentanyl may produce bradycardia. Fentanyl should be administered with caution to patients with bradyarrhythmias.</p><p>&nbsp;</p><p><strong><u>Concomitant Use of Central Nervous System Depressants</u></strong></p><p>When patients are receiving FENTANYL TRANSDERMAL SYSTEM, the dose of additional opioids or other CNS depressant drugs (including alcohol beverages, benzodiazepines, general anesthetics, muscle relaxants and sedating over-the-counter antihistamines) should be reduced by at least 50%. The concomitant use of CNS depressants may result in hypotension, respiratory depression and profound sedation, coma or death (see <strong>INTERACTION </strong><strong>WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION).</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Concomitant Use of CYP3A4 Inhibitors</u></strong></p><p>The concomitant use of FENTANYL TRANSDERMAL SYSTEM with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazodone, verapamil, diltiazem, amiodarone, amprenavir, fosamprenavir, aprepitant, fluconazole, erythromycin and grapefruit juice) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In this situation special patient care and observation are appropriate. Therefore, the concomitant use of transdermal fentanyl and CYP 3A4 inhibitors is not recommended unless the patient is closely monitored, for an extended period of time, for signs of respiratory depression, with dosage adjustments made as warranted (see <strong>INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION</strong>).</p><p>&nbsp;</p><p><strong><u>Potential for Abuse and Diversion</u></strong></p><p>FENTANYL TRANSDERMAL SYSTEM contains a high concentration of a potent opioid, fentanyl, which along with other opioids of the morphine type has high potential for abuse and associated risk of fatal overdose due to respiratory depression. The high fentanyl content in FENTANYL TRANSDERMAL SYSTEM patches may be a particular target for abuse and diversion, with alternative routes of administration potentially resulting in overdose from uncontrolled delivery of the opioid.</p><p>This risk should be considered when administering, prescribing, or dispensing FENTANYL TRANSDERMAL SYSTEM in situations where the healthcare professional is concerned about increased risk of misuse, abuse or diversion.</p><p>Concerns about abuse, addiction and diversion should not prevent the proper management of pain. Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. All patients receiving opioids should be routinely monitored for signs of misuse and abuse.</p><p>Since FENTANYL TRANSDERMAL SYSTEM may be diverted for non-medical use, careful record keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised. Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs (see <strong><u>Dependence/Tolerance)</u>.</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Dependence/Tolerance Drug</u> </strong></p><p><strong>Drug Dependence vs. Abuse</strong></p><p>Fentanyl is an opioid substance and can produce drug dependence similar to that produced by morphine. FENTANYL TRANSDERMAL SYSTEM, therefore, has the potential for abuse.</p><p>However, tolerance as well as both physical and psychological dependence may develop upon repeated administration of opioids, and are not by themselves evidence of an addictive disorder or abuse. Iatrogenic addiction following appropriate opioid administration for relief of severe pain is relatively rare. Physicians should not let concerns of physical dependence deter them from using adequate amounts of opioids in the management of severe pain when such use is indicated. Patients at increased risk of opioid abuse may still be appropriately treated with modified-release opioid formulations; however, these patients will require monitoring for signs of misuse, abuse or addiction.</p><p>&nbsp;</p><p><strong>Drug or Alcohol Dependence</strong></p><p>Use of FENTANYL TRANSDERMAL SYSTEM in combination with CNS depressants, including alcohol, can result in increased risk to the patient (see <strong>INTERACTION </strong><strong>WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION).</strong></p><p>FENTANYL TRANSDERMAL SYSTEM should be used with caution in individuals who have a history of drug or alcohol abuse, especially those outside a medically controlled environment. While the management of severe pain in patients with a history of addiction requires special consideration, the use of opioids is not necessarily contraindicated in these patients. There may also be an increased risk of diversion in this population; this risk may be decreased by attention to patterns of prescription requests, and by prescribing opioids only as part of an ongoing relationship between a patient and a healthcare provider.</p><p>&quot;Drug seeking&quot; behaviour includes emergency calls or visits near the end of office hours; refusal to undergo appropriate examination, testing or referral; repeated &quot;loss&quot; of prescriptions; tampering with prescriptions; &quot;doctor shopping&quot; to obtain additional prescriptions; and reluctance to provide prior medical records or contact information for other treating physician(s).</p><p>&nbsp;</p><p><strong><u>Head Injuries and Increased Intracranial Pressure</u></strong></p><p>FENTANYL TRANSDERMAL SYSTEM should not be used in patients who may be particularly susceptible to the intracranial effects of CO2&nbsp;retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. Opioids may obscure the clinical course of patients with head injury. FENTANYL TRANSDERMAL SYSTEM should be used with caution in patients with brain tumours.</p><p>&nbsp;</p><p><strong><u>Perioperative Considerations</u></strong></p><p>FENTANYL TRANSDERMAL SYSTEM is contraindicated for perioperative pain relief, especially in the elective surgical setting. &nbsp;In the case of planned chordotomy, or other pain- relieving operations, patients should not be treated with FENTANYL TRANSDERMAL SYSTEM within 72 hours before the operation and should not be used in the immediate post-operative period. Thereafter, if FENTANYL TRANSDERMAL SYSTEM is to be continued after the patient recovers from the post-operative period, a new dosage should be administered in accordance with the changed need for pain relief, if needed, and to reduce the risk of withdrawal in highly opioid-tolerant patients.</p><p>The administration of analgesics in the perioperative period should be managed by health care providers with adequate training and experience (e.g., an anesthesiologist) (see <strong>CONTRAINDICATIONS</strong>).</p><p>&nbsp;</p><p><strong><u>Hepatic/Biliary/Pancreatic</u></strong></p><p>Because of the hepatic metabolism of fentanyl, FENTANYL TRANSDERMAL SYSTEM should be used with caution in patients with liver dysfunction.</p><p>FENTANYL TRANSDERMAL SYSTEM may cause spasm of the sphincter of Oddi and should be used with caution in patients with biliary tract disease, including acute pancreatitis. Opioids like fentanyl may cause increases in the serum amylase concentration.</p><p><strong><u>If patients with hepatic impairment receive FENTANYL TRANSDERMAL SYSTEM, they</u> <u>should be observed carefully for signs of fentanyl toxicity and the dose of FENTANYL </u>&nbsp;<u>TRANSDERMAL SYSTEM reduced if necessary.</u></strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Renal</u></strong></p><p>Because of the renal excretion of fentanyl, FENTANYL TRANSDERMAL SYSTEM should be used with caution in patients with kidney dysfunction.</p><p><strong><u>If patients with renal impairment receive FENTANYL TRANSDERMAL SYSTEM, </u>&nbsp;<u>they should be observed carefully for signs of fentanyl toxicity and the dose reduced if </u>&nbsp;<u>necessary.</u></strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Respiratory</u></strong><strong>&nbsp;</strong></p><p><strong>Respiratory</strong><strong> </strong><strong>Depression</strong></p><p>As with all potent opioids, some patients may experience significant respiratory depression (including respiratory distress, apnea, bradypnea, hypoventilation, dyspnea) with FENTANYL TRANSDERMAL SYSTEM; caution must be exercised and patients carefully observed for untoward reactions. While most patients using fentanyl transdermal system chronically develop tolerance to fentanyl-induced hypoventilation, episodes of slowed respiration may occur at any time during therapy. A small number of patients have experienced clinically significant hypoventilation with fentanyl transdermal system; medical intervention generally was not required in these instances. The incidence of respiratory depression increases as the FENTANYL TRANSDERMAL SYSTEM dose is increased.</p><p>Hypoventilation can occur throughout the therapeutic range of fentanyl serum concentrations. However, the risk of hypoventilation increases at serum fentanyl concentrations greater than 2 ng/mL in non-opioid-tolerant patients, especially for patients who have an underlying pulmonary condition or who receive usual doses of opioids or other CNS drugs associated with &nbsp;hypoventilation in addition to FENTANYL TRANSDERMAL SYSTEM (see <strong>INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION, Overview, Additive Effects of Other CNS Depressants</strong>). The use of FENTANYL TRANSDERMAL SYSTEM should be monitored by clinical evaluation. As with other drug-level measurements, serum fentanyl concentrations may be useful clinically, although they do not reflect patients&#39; sensitivity to fentanyl and should not be used by physicians as a sole indicator of effectiveness or toxicity.</p><p>The duration of the respiratory depressant effect of FENTANYL TRANSDERMAL SYSTEM may extend beyond the removal of the system (see also <strong>OVERDOSAGE </strong>concerning respiratory depression).</p><p>&nbsp;</p><p><strong>Gastrointestinal Tract</strong></p><p>Opioids increase the tone and decrease the propulsive contractions of the smooth muscle of the gastrointestinal tract. The resultant prologation in gastrointestinal transit time may be responsible for the constipating effect of fentanyl. Patients should be advised on measures to prevent constipation and prophylactic laxative use should be considered. Extra caution should be used in patients with chronic constipation. If paralytic ileus is present or suspected, treatment with FENTANYL TRANSDERMAL SYSTEM should be stopped (see <strong>PHARMACOLOGICAL PROPERTIES, Pharmacodynamics</strong>).</p><p>&nbsp;</p><p><strong>Use in Patients with Chronic Pulmonary Disease</strong></p><p>Fentanyl should be used with caution in patients with chronic pulmonary disease, patients with decreased respiratory reserve and others with potentially compromised respiration. Normal analgesic doses of opioids may further decrease respiratory drive in these patients to the point of respiratory failure.</p><p>&nbsp;</p><p><strong><u>Information for Patients</u></strong></p><p>Consumer information sheet is included in the package of FENTANYL TRANSDERMAL SYSTEM patches dispensed to the patient.</p><p>Patients receiving FENTANYL TRANSDERMAL SYSTEM patches should be given the following instructions by the physician:</p><p>1. Patients should be informed that accidental ingestion or use by individuals (including children) other than the patient for whom it was originally prescribed, may lead to severe, even fatal, consequences.</p><p>2. Patients should be advised that FENTANYL TRANSDERMAL SYSTEM patches contain fentanyl, an opioid pain medicine similar to morphine, hydromorphone, methadone, oxycodone, and oxymorphone.</p><p>3. Patients should be advised that each FENTANYL TRANSDERMAL SYSTEM patch may be worn continuously for 72 hours, and that each patch should be applied to a different skin site after removal of the previous transdermal patch.</p><p>4. Patients should be advised that FENTANYL TRANSDERMAL SYSTEM patches should be applied to intact, non-irritated, and non-irradiated skin on a flat surface such as the chest, back, flank, or upper arm. Additionally, patients should be advised of the following:</p><p>&middot; In young children or persons with cognitive impairment, the patch should be put on the upper back to lower the chances that the patch will be removed and placed in the mouth.</p><p>&middot; Hair at the application site should be clipped (not shaved) prior to patch application.</p><p>&middot; If the site of FENTANYL TRANSDERMAL SYSTEM application must be cleansed prior to application of the patch, do so with clear water.</p><p>&middot; Do not use soaps, oils, lotions, alcohol, or any other agents that may irritate the skin or alter its characteristics.</p><p>&middot; Allow the skin to dry completely prior to patch application.</p><p>5. Patients should be advised that FENTANYL TRANSDERMAL SYSTEM should be applied immediately upon removal from the sealed package and after removal of the protective liner.</p><p>Additionally the patient should be advised of the following:</p><p>&middot; The FENTANYL TRANSDERMAL SYSTEM patch should not be used if the seal is broken, or if it is altered, cut, or damaged in any way prior to application. The transdermal patch should be pressed firmly in place with the palm of the hand for 30 seconds, making sure the contact is complete, especially around the edges.</p><p>&middot; The patch should not be folded so that only part of the patch is exposed.</p><p>6. Patients should be advised that, while wearing the patch, they should avoid exposing the FENTANYL TRANSDERMAL SYSTEM application site to direct external heat sources, such as:</p><p>&middot; heating pads,</p><p>&middot; electric blankets,</p><p>&middot; heat lamps,</p><p>&middot; saunas,</p><p>&middot; hot tubs, and</p><p>&middot; heated water beds, etc.</p><p>&nbsp;</p><p>7. Patients should be advised that there is a potential for temperature-dependent increase in fentanyl release from the patch that could result in an overdose of fentanyl; therefore, if patients develop a high fever while wearing the patch they should contact their physician.</p><p>8. Patients should be advised that if they experience problems with adhesion of the FENTANYL TRANSDERMAL SYSTEM patch, they may tape the edges of the patch with first aid tape. If problems with adhesion persist, patients may overlay the patch with a transparent adhesive film dressing.</p><p>9. Patients should be advised that if the patch falls off before 72 hours a new patch may be applied to a different skin site.</p><p>10. Patients should be advised to fold (so that the adhesive side adheres to itself) and immediately flush down the toilet used FENTANYL TRANSDERMAL SYSTEM patches after removal from the skin.</p><p>11. Patients should be instructed that, if the drug adhesive layer accidentally contacts the skin, the area should be washed clean with clear water and not soap, alcohol, or other chemicals, because these products may increase the ability of fentanyl to go through the skin.</p><p>12. Patients should be advised that the dose of FENTANYL TRANSDERMAL SYSTEM should NEVER be adjusted without the prescribing health care professional&#39;s instruction.</p><p>13. Patients should be advised that FENTANYL TRANSDERMAL SYSTEM may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating machinery).</p><p>14.&nbsp;Patients should be advised to refrain from any potentially dangerous activity when starting on FENTANYL TRANSDERMAL SYSTEM or when their dose is being adjusted, until it is established that they have not been adversely affected.</p><p>15. Patients should be advised that FENTANYL TRANSDERMAL SYSTEM should not be combined with alcohol or other CNS depressants (e.g., sleep medications, tranquilizers) because dangerous additive effects may occur, resulting in serious injury or death.</p><p>16. Patients should be advised to consult their physician or pharmacist if other medications are being or will be used with FENTANYL TRANSDERMAL SYSTEM.</p><p>17. Patients should be advised of the potential for severe constipation.</p><p>18. Patients should be advised that if they have been receiving treatment with FENTANYL TRANSDERMAL SYSTEM and cessation of therapy is indicated, it may be appropriate to taper the FENTANYL TRANSDERMAL SYSTEM dose, rather than abruptly discontinue it, due to the risk of precipitating withdrawal symptoms.</p><p>19. Patients should be advised that FENTANYL TRANSDERMAL SYSTEM contains fentanyl, a drug with high potential for abuse.</p><p>20. Patients, family members and caregivers should be advised to protect FENTANYL TRANSDERMAL SYSTEM from theft or misuse in the work or home environment.</p><p>21. Patients should be advised that FENTANYL TRANSDERMAL SYSTEM should never be given to anyone other than the individual for whom it was prescribed because of the risk of death or other serious medical problems to that person for whom it was not intended.</p><p>22. Patients should be instructed to keep FENTANYL TRANSDERMAL SYSTEM in a secure place out of the reach of children due to the high risk of fatal respiratory depression.</p><p>23. When FENTANYL TRANSDERMAL SYSTEM is no longer needed, the unused patches should be removed from their pouches, folded so that the adhesive side of the patch adheres to itself, and flushed down the toilet.</p><p>24. Women of childbearing potential who become or are planning to become pregnant should be advised to consult a physician prior to initiating or continuing therapy with FENTANYL TRANSDERMAL SYSTEM.</p><p>25. Patients should be informed that accidental exposure or misuse may lead to death or other serious medical problems.</p><p>26. Patients should be informed that, if the patch dislodges and accidentally sticks to the skin of another person, they should immediately take the patch off, wash the exposed area with water and seek medical attention for the accidentally exposed individual.</p><p>27. Patients should be informed that, because FENTANYL TRANSDERMAL SYSTEM contains aluminum, they are recommended to remove the patch before undergoing any magnetic resonance imaging scan to avoid possible burns.</p><p>&nbsp;</p><p><strong>Pediatrics (&lt;18 years of age):</strong></p><p>Used with caution as life-threatening respiratory depression has been reported in some pediatric patients receiving fentanyl transdermal system. The use of FENTANYL TRANSDERMAL</p><p>SYSTEM in children under 18 years of age is not recommended, as dosage requirements for the safe and efficacious use of FENTANYL TRANSDERMAL SYSTEM have not been established for this patient population. Life-threatening hypoventilation has been reported in some pediatric patients receiving fentanyl transdermal system.</p><p>&nbsp;</p><p><strong>Elderly and Debilitated Patients: </strong></p><p>In elderly, cachectic, or debilitated patients, FENTANYL TRANSDERMAL SYSTEM may have altered pharmacokinetics due to poor fat stores, muscle wasting or altered clearance (see <strong>DOSAGE AND ADMINISTRATION)</strong>. Therefore, it may be appropriate, according to clinical judgment, to initiate these patients on a lower FENTANYL TRANSDERMAL SYSTEM dose than that which the conversion tables recommend (see <strong>CONTRAINDICATIONS). </strong>As with all FENTANYL TRANSDERMAL SYSTEM patients, they should be carefully monitored for pain levels and adverse events, particularly hypoventilation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Overview</u></strong></p><p><strong>Additive</strong><strong> </strong><strong>Effects</strong><strong> </strong><strong>of</strong><strong> </strong><strong>Other</strong><strong> </strong><strong>CNS</strong><strong> </strong><strong>Depressants</strong></p><p>Hypoventilation, hypotension and profound sedation or coma may occur with the concomitant use of other central nervous system depressants (including other opioids, sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers); skeletal muscle relaxants, sedating antihistamines, and alcoholic beverages may produce additive depressant effects. When combined therapy is contemplated, the dose of each agent should be reduced by at least 50%.</p><p>&nbsp;</p><p><strong><u>Drug-Drug Interactions</u></strong></p><p><strong>CYP3A4</strong><strong> </strong><strong>Inhibitors</strong></p><p>Fentanyl, a high clearance drug, is rapidly and extensively metabolized mainly by the human cytochrome P450 3A4 isoenzyme system (CYP3A4); therefore, potential interactions may occur when fentanyl transdermal system is given concurrently with agents that affect CYP3A4 activity. The concomitant use of transdermal fentanyl with ritonavir or other potent <u>3A4 inhibitors </u>such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazodone, verapamil, diltiazem, amiodarone, amprenavir, fosamprenavir, aprepitant, fluconazole, erythromycin and grapefruit juice may result in an increase in fentanyl plasma concentrations which could increase or prolong adverse drug effects and may cause serious respiratory depression (see also <strong>WARNINGS AND PRECAUTIONS, <u>Concomitant Use of CYP3A4 Inhibitors</u></strong>). In this situation, special patient care and observation are appropriate. The concomitant use of CYP3A4 inhibitors and FENTANYL TRANSDERMAL SYSTEM is not recommended, unless the patient is closely monitored.</p><p>CYP3A4 Inducers Coadministration with agents that induce 3A4 activity suchasrifampicin, carbamazepine, phenobarbital, phenytoin mayreduce the efficacyof FENTANYLTRANSDERMALSYSTEM. This may require adose adjustment of transdermal fentanyl. After stopping thetreatmentofa CYP3A4 inducer, the effects of the inducer decline gradually and mayresult in an increaseinfentanyl plasma concentration which could increase orprolong both the therapeutic and adverse effects, and maycause serious respiratory depression.</p><p>&nbsp;</p><p><strong>Monoamine oxidase (MAO) inhibitors</strong></p><p>Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics. Since the safety of fentanyl in this regard has not been established, the use of fentanyl in patients who have received MAO inhibitors during the previous 14-day period is not recommended. Conversely, the use of MAO inhibitors in patients who have received fentanyl in the previous 14-day period is not recommended.</p><p>&nbsp;</p><p><strong>Serotonergic Drugs</strong></p><p><strong>Coadministration</strong><strong> of fentanyl with a serotonergic agent, such as a Selective Serotonin Re- uptake Inhibitor or a Serotonin Norepinephrine Re-uptake Inhibitor, may increase the risk of serotonin syndrome, a potentially life-threatening condition (see also </strong>UNDESIRABLE EFFECTS, Post-Market Adverse Drug Reactions<strong>).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnant</strong><strong> </strong><strong>Women:</strong></p><p>Fentanyl has been shown to impair fertility and to have an embryocidal effect in rats when given in intravenous doses 0.3 times the human dose for a period of 12 days. No evidence of teratogenic effects has been observed after the administration of fentanyl to rats.</p><p>The safe use of fentanyl has not been established with respect to possible adverse effects upon human fetal development. Neonatal withdrawal syndrome has been reported in newborn infants with chronic maternal use of fentanyl transdermal system during pregnancy. Therefore, FENTANYL TRANSDERMAL SYSTEM should not be used in women of childbearing potential unless, in the judgment of the physician, the potential benefits outweigh the possible hazards.</p><p>Use of FENTANYL TRANSDERMAL SYSTEM during childbirth is not recommended because fentanyl passes through the placenta and may cause respiratory depression in the newborn child.</p><p>&nbsp;</p><p><strong>Nursing Women:</strong></p><p>Fentanyl is excreted in human milk, therefore FENTANYL TRANSDERMAL SYSTEM is not recommended for use in nursing women because of the possibility of effects in their infants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FENTANYL TRANSDERMAL SYSTEM may impair mental and/or physical ability required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Patients using FENTANYL TRANSDERMAL SYSTEM should not drive or operate dangerous machinery unless they are tolerant to the effects of the drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Clinical</u></strong><strong><u> </u></strong><strong><u>Trial</u></strong><strong><u> </u></strong><strong><u>Adverse</u></strong><strong><u> </u></strong><strong><u>Drug</u></strong><strong><u> </u></strong><strong><u>Reactions</u></strong></p><p><strong>Cancer</strong><strong> </strong><strong>Trials</strong><strong> </strong><strong>- Adults</strong></p><p><u>Open-Label and Active-Control Double-Blind Studies</u></p><p>The safety of fentanyl transdermal system has been evaluated in 153 cancer patients and 357 postoperative patients. The duration of fentanyl transdermal system use varied in cancer patients: 56% of patients used fentanyl transdermal system for over 30 days, 28% continued treatment for more than 4 months, and 10% used fentanyl transdermal system for more than 1 year. In cancer patients, fentanyl transdermal system was administered in doses of 25 mcg/h to 600 mcg/h. Patients with acute pain used fentanyl transdermal system for 1 to 3 days.</p><p>Respiratory depression, the most serious adverse reaction, was observed in 3 (2%) of the cancer patients, 13 (4%) of postoperative patients. Hypotension and hypertension were observed in 11 (3%) and 4 (1%) of the opioid-naive patients.</p><p>&nbsp;</p><p><u>Placebo-Controlled Study</u></p><p>Adverse events occurring at a greater frequency than placebo were identified in a placebo- controlled clinical trial of fentanyl transdermal system (25 mcg/h to 100 mcg/h) in cancer patients. Patients were stabilized on morphine for 7 days, and those who achieved adequate pain relief (n=131) were then switched to fentanyl transdermal system. During the initial open-label dose- titration and stabilization period of 15 days, a total of 43 patients dropped out; four experienced dyspnea, 3 nausea and 1 severe hallucinations.</p><p>Following this stabilization period, the nine-day double-blind period began, with patients randomized to either continue the dose of fentanyl transdermal system achieved during stabilization (n=47) or to switch to placebo (n=48). Rescue morphine was available. The median dose of fentanyl transdermal system was 50 mcg/h. Adverse events during this period, as reported by at least 1 fentanyl transdermal system patient (2.1%), and with a higher frequency of occurrence versus placebo include: vomiting (4.3% vs 0%), and the following events at 2.1% vs 0%: abscess, vertigo, hemorrhage, abdominal pain and jaundice.</p><p>&nbsp;</p><p><strong>Chronic Non-Cancer Pain Trials - Adults</strong></p><p>The safety findings from the two primary trials (FEN-INT-12, n=248 patients; and FEN-INT-13, n=532 patients) are described below (see <strong>Product Monograph, Part II: CLINICAL TRIALS, </strong>&nbsp;<u>Chronic Non- Cancer Pain (CNCP) Trials </u>for methodological details on the trials).</p><p>&nbsp;</p><p><u>Safety Findings</u></p><p>Adverse events related to respiratory depression (reported as either bradypnea or hypoventilation) have been reported in 3/780 (0.4%) of the CNCP patients, leading to discontinuation in all three cases.</p><p>There were nine deaths (all in the one-year trial): four were due to cardiac events, three to pneumonia, one to a cerebrovascular event, and one to cancer.</p><p>The discontinuation rates were 16% for the one-month crossover trial (FEN-INT-12) and 43% for the one-year trial (FEN-INT-13).</p><p>Of the 780 patients, 149 (19%) received less than one month fentanyl transdermal system treatment, 272 (35%) used fentanyl transdermal system for one to six months, 137 (18%) for six months to one year and 222 patients (28%) continued treatment for more than one year.</p><p>Among patients who completed the one-year trial (n=301 of 530 ITT patients), the mean dose at the 12-month endpoint was 90.4 mcg/h, with the most common dose being 75 mcg/h.</p><p>&nbsp;</p><p><u>Most Common Adverse Events</u></p><p>A causal relationship of adverse events to fentanyl transdermal system was not always determined. The most commonly observed adverse events in the non-cancer chronic pain clinical trials, regardless of causal relationship, are: nausea or vomiting, somnolence, constipation, sweating, headache, dizziness, pruritus and depression.</p><p>Other reported Undesirable effects occurring in &gt; 1% of patients that are probably or likely related to fentanyl transdermal system treatment are:</p><p>&nbsp;</p><p><em><u>Application</u></em><em><u> </u></em><em><u>Site:</u></em><em><u> </u></em>application site reaction</p><p><em><u>Body as a Whole</u>: </em>fatigue, pain, malaise, asthenia, hot flushes, withdrawal syndrome, back pain, rigors, temperature changed sensation</p><p><em><u>Central</u></em><em><u> </u></em><em><u>&amp; Peripheral Nervous System</u></em><em>:</em><em> </em>tremor, vertigo, hypertonia</p><p><em><u>Gastrointestinal System:&nbsp;</u></em>dry mouth, diarrhea, abdominal pain, dyspepsia</p><p><em><u>Heart Rate and Rhythm:&nbsp;</u></em>palpitation</p><p><em><u>Liver</u></em><em><u> </u></em><em><u>and Biliary</u></em><em><u> </u></em><em><u>System</u></em><em>:</em><em> </em>hepatic enzymes increased, gamma-GT increased</p><p><em><u>Metabolic</u></em><em><u> </u></em><em><u>and </u></em><em><u>Nutritional</u></em><em>:</em><em> </em>weight decreased, LDH increased</p><p><em><u>Psychiatric</u>: </em>anorexia, anxiety, confusion, insomnia, nervousness, agitation, hallucination, concentration impaired, emotional lability, amnesia</p><p><em><u>Respiratory</u></em><em><u> </u></em><em><u>System:&nbsp;</u></em>dyspnea</p><p><em><u>Skin</u></em><em><u> </u></em><em><u>and Appendages</u></em><em>:</em><em> </em>rash erythematous, skin disorder</p><p>&nbsp;</p><p><strong>Chronic Pain Trials - Pediatrics</strong></p><p>The safety of fentanyl transdermal system has been evaluated in 293 opioid-tolerant pediatric patients (age 18 years or less) with chronic pain, with n=63 receiving fentanyl transdermal system for at least 2 months. Approximately 60% of the patients had underlying pain due to malignancy. The number of patients in the lower age ranges were as follows: n=2 patients &lt; 2 years old; n=65 patients 2 to &lt; 6 years old; n=100 patients 6 to &lt;12 years old. The most commonly reported adverse events regardless of causality include: vomiting (14.3%), nausea (11.6%), constipation (9.2%), pruritus (8.2%), and somnolence (5.8%). Three patients experienced respiratory depression within 96 hours of beginning fentanyl transdermal system; two of these patients died. The underlying condition of the patients contributed to the deaths. The third patient&#39;s decreased respiratory rate was resolved after temporary discontinuation of fentanyl transdermal system.</p><p>Dosing recommendations for the safe and effective use of fentanyl transdermal system in this patient population have not been established, in view of the combination of:</p><p>i) the variety of factors which could lead to overexposure from fentanyl transdermal system in children as compared to adults (including smaller body weight and significantly different body surface area; differential skin characteristics; potential for magnification, compared to adults, of the impact of amount of body fat stores, muscle wasting, fever, external heat), and</p><p>ii) the limitations in both formal PK data (see <strong>PHARMACOLOGICAL PROPERTIES,</strong><strong> </strong><strong><u>Pharmacokinetics,</u></strong><strong><u> </u></strong><strong><u>Special</u></strong><strong><u> </u></strong><strong><u>Populations</u></strong><strong><u> </u></strong><strong><u>and</u></strong><strong><u> </u></strong><strong><u>Conditions)</u></strong><strong><u> </u></strong>and exposure data (as above).</p><p>&nbsp;</p><p><strong><u>Post-Market Adverse Drug Reactions</u></strong></p><p>In post-marketing experience, deaths from hypoventilation have been reported in cases of inappropriate use of fentanyl transdermal system.</p><p>Other opioid-related Undesirable effects include: nausea, vomiting, constipation, hypotension, bradycardia, somnolence, headache, confusion, hallucination, euphoria, pruritus, sweating, pyrexia tachycardia, paresthesia, sexual dysfunction, and urinary retention.</p><p>Skin reactions such as rash, erythema and itching have occasionally been reported. These reactions usually resolve within 24 hours or upon removal of the patch.</p><p>There have been very rare reports of anaphylactic and anaphylactoid reaction, including Stevens- Johnson syndrome, airway constriction, swelling, anaphylactic shock, and two deaths that occurred within 24 hours of the anaphylactic reaction. In one case, it was the care-giver of the patient who experienced dyspnea, urticaria and swelling, within ten minutes of applying the patch to the patient.</p><p>There have also been rare reports of convulsions, including clonic convulsions and grand mal convulsions. In two cases, vegetative state or coma was reported to immediately follow the convulsions.</p><p>Opioid withdrawal symptoms, such as nausea, vomiting, diarrhea, anxiety and shivering are possible in some patients after conversion from their previous opioid analgesic to fentanyl transdermal system or if therapy is stopped suddenly. There have been very rare reports of newborn infants experiencing neonatal withdrawal syndrome when mothers chronically used fentanyl transdermal system during pregnancy (see <strong>WARNINGS AND PRECAUTIONS: Special Populations, Pregnant Women</strong>).</p><p>Post-marketing reports describe patients with symptoms suggestive of, or diagnostic of, serotonin syndrome following the concomitant use of fentanyl with a serotonergic drug, such as a Selective Serotonin Re-uptake Inhibitor or a Serotonin Norepinephrine Re-uptake Inhibitor (see also <strong>INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF</strong></p><p>INTERACTION, Drug-Drug Interactions).</p><p><strong>&nbsp;</strong></p><p>-&nbsp; <strong>To report any side effect(s):</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Saudi Arabia:</em></strong></p><p><strong>The</strong><strong> </strong><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Drug Safety Centre (NPC)</strong></p><p>Fax: +966‐11‐205‐7662</p><p>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>Toll free phone: 8002490000</p><p>E‐mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.</p></td></tr></tbody></table><p><strong><u>Symptoms</u></strong></p><p>The manifestations of fentanyl overdosage are an extension of its pharmacologic actions with the most serious effect being respiratory depression.</p><p>&nbsp;</p><p><strong><u>Treatment</u></strong></p><p>For management of respiratory depression, immediate countermeasures include removing the FENTANYL TRANSDERMAL SYSTEM patch and physically or verbally stimulating the patient. These actions can be followed by administration of a specific opioid antagonist such as naloxone. The duration of respiratory depression following an overdose may be longer than the effects of the opioid antagonist&#39;s action (the half-life of naloxone ranges from 30 to 81 minutes). The interval between IV antagonist doses should be carefully chosen because of the possibility of re- narcotization after system removal; repeated administration of naloxone may be necessary.</p><p>Reversal of the opioid effect may result in acute onset of pain and release of catecholamines.</p><p>If the clinical situation warrants, establish and maintain a patent airway, administer oxygen and assist or control respiration as indicated, and use an oropharyngeal airway or endotracheal tube if necessary. If depressed respiration is associated with muscular rigidity, an intravenous neuromuscular blocking agent may be required to facilitate assisted or controlled respiration.</p><p>Adequate body temperature and fluid intake should be maintained.</p><p>If severe or persistent hypotension occurs, the possibility of hypovolemia should be considered, and managed with appropriate parenteral fluid therapy.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fentanyl is an opioid analgesic which interacts predominantly with the &micro;-opioid receptor. Fentanyl produces analgesia, sedation, respiratory depression, constipation, and physical dependence but appears to have less emetic activity than other opioid analgesics. Fentanyl may produce muscle rigidity, miosis, cough reflex suppression, alterations in mood, bradycardia and bronchoconstriction.</p><p>Analgesic blood levels of fentanyl may cause nausea and vomiting directly by stimulating the chemoreceptor trigger zone, but nausea and vomiting are significantly more common in ambulatory than in recumbent patients, as is postural syncope.</p><p>Opioids increase the tone and decrease the propulsive contractions of the smooth muscle of the gastrointestinal tract. The resultant prolongation in gastrointestinal transit time may be responsible for the constipating effect of fentanyl. Because opioids may increase biliary tract pressure, some patients with biliary colic may experience worsening rather than relief of pain.</p><p>While opioids generally increase the tone of urinary tract smooth muscle, the net effect tends to be variable, in some cases producing urinary urgency, in others, difficulty in urination.</p><p>At therapeutic dosages, fentanyl usually does not exert major effects on the cardiovascular system. However, some patients may exhibit orthostatic hypotension and fainting.</p><p>Histamine assays and skin wheal testing in man indicate that histamine release rarely occurs with fentanyl. Assays in man show no clinically significant histamine release in dosages up to 50 mcg/kg.</p><p>Both the minimum effective concentration and the concentration at which toxicity occurs rise with increasing tolerance. The rate of development of tolerance varies widely among individuals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FENTANYL TRANSDERMAL SYSTEM provides continuous systemic delivery of fentanyl for up to 72 hours. Fentanyl is released along the concentration gradient existing between the drug adhesive layer of the system and the lower concentration in the skin.</p><p>&nbsp;</p><p><strong>Adults</strong></p><p><u>Fentanyl Transdermal System</u></p><p><u>Absorption:</u></p><p>Fentanyl is released at a relatively constant rate. The concentration gradient existing between the matrix and the lower concentration in the skin drives drug release. Following initial fentanyl transdermal system administration, serum fentanyl concentrations increase gradually, generally leveling off between 12 and 24 hours and remaining relatively constant for the remainder of the 72-hour application period. Peak serum levels of fentanyl generally occur between 24 and 72 hours after the first application.</p><p>Serum fentanyl concentrations achieved are proportional to the fentanyl transdermal system delivery rate (see Table 1.3). With continuous use, serum fentanyl concentrations continue to rise for the first few system applications. After several sequential 72-hour applications, patients reach and maintain a steady- state serum concentration that is determined by individual variation in skin permeability and body clearance of fentanyl.</p><p>&nbsp;</p><p><strong>Table 1.3</strong></p><p><strong>Pharmacokinetic</strong><strong> </strong><strong>Parameters</strong><strong> </strong><strong>of</strong><strong> </strong><strong>TTS</strong><strong> </strong><strong>(fentanyl)</strong><strong> </strong><strong>in</strong><strong> </strong><strong>Adults</strong></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>&nbsp;</td><td><p><strong>Mean (SD) </strong></p><p><strong>Maximal Concentration </strong></p><p><strong>Cmax&nbsp;(ng/mL)</strong></p></td><td><p><strong>Mean (SD) Time to Maximal Concentration<strong> </strong>T</strong><strong>max</strong><strong>&nbsp;</strong><strong>(h)</strong></p></td></tr><tr><td><p>Fentanyl Transdermal System 25 mcg/h</p></td><td><p>0.6 (0.3)</p></td><td><p>38.1 (18.0)</p></td></tr><tr><td><p>Fentanyl Transdermal System 50 mcg/h</p></td><td><p>1.4 (0.5)</p></td><td><p>34.8 (15.4)</p></td></tr><tr><td><p>Fentanyl Transdermal System 75 mcg/h</p></td><td><p>1.7 (0.7)</p></td><td><p>33.5 (14.5)</p></td></tr><tr><td><p>Fentanyl Transdermal System 100 mcg/h</p></td><td><p>2.5 (1.2)</p></td><td><p>36.8 (15.7)</p></td></tr></tbody></table><p>After fentanyl transdermal system removal, serum fentanyl concentrations decline gradually, falling about 50% in approximately 17 (range 13-22) hours. Continued absorption of fentanyl from the skin accounts for a slower disappearance of the drug from the serum than is seen after an IV infusion, where the apparent half-life ranges from 3-12 hours.</p><p>&nbsp;</p><p><u>Distribution: </u></p><p>The average volume of distribution for fentanyl is 6 L/kg (range 3-8, n=8). The average clearance in patients undergoing various surgical procedures is 46 L/h (range 27-75, n=8). The plasma protein binding for fentanyl is about 84%.</p><p>&nbsp;</p><p><u>Metabolism: </u></p><p>Skin does not appear to metabolize fentanyl delivered transdermally. Fentanyl is metabolized primarily in the liver. This was determined in a human keratinocyte cell assay and in clinical studies in which 92% of the dose delivered from the system was accounted for as unchanged fentanyl that appeared in the systemic circulation. In humans, the drug is metabolized primarily by N-dealkylation to norfentanyl and other inactive metabolites.</p><p>&nbsp;</p><p><u>Excretion: </u></p><p>Within 72 hours of IV fentanyl administration, approximately 75% of the fentanyl dose is excreted in urine, mostly as metabolites, with less than 10% representing unchanged drug.</p><p>Approximately 9% of the dose is recovered in the feces, primarily as metabolites.</p><p>&nbsp;</p><p><strong><u>Special Populations and Conditions</u></strong></p><p><strong>Pediatrics Under 18 Years of Age</strong>: In a pharmacokinetic study with non-opioid-tolerant patients, 8 children aged 1.5 to 5 years old on <u>25 mcg/h </u>patches were compared to 8 adults on <u>50 mcg/h</u> patches. The comparative &quot;dose per mean body weight&quot; i.e. mcg/h/kg was 1.67 for children vs 0.67 for adults. Mean Cmax&nbsp;was 50% higher in the children and mean AUC ~25% higher, with both mean Tmax&nbsp;and mean half-life shorter (approx. 50% and 75% of the adult values, respectively). For 6 of the 8 children, there was no apparent plateau in plasma concentrations. Adjusting for either body weight or body surface area, clearance in pediatric subjects was found to be about 20%-40% higher than in adults.</p><p>Analyses of population pharmacokinetics data in pediatrics indicate that the variability in fentanyl AUC and Cmax&nbsp;values at steady state (Css) correlated with changes in body surface area (BSA) values observed in subjects. An increase in BSA of 0.1 m2&nbsp;is predicted to result in a 4.8% increase in clearance and 4.6% decrease in Css.</p><p>Dosing recommendations for the safe and effective use of fentanyl transdermal systems in this patient population have not been established, in view of the combination of:</p><p>i) the variety of factors which could lead to overexposure from fentanyl transdermal systems in children as compared to adults (including smaller body weight and significantly different body surface area; differential skin characteristics; potential for magnification, compared to adults, of the impact of amount of body fat stores, muscle wasting, fever, external heat), and</p><p>ii) the limitations in both formal PK data (as above) and exposure data (see <strong>ADVERSE</strong><strong> </strong><strong>REACTIONS,</strong><strong> </strong><strong><u>Clinical</u></strong><strong><u> </u></strong><strong><u>Trial</u></strong><strong><u> </u></strong><strong><u>Adverse</u></strong><strong><u> </u></strong><strong><u>Drug</u></strong><strong><u> </u></strong><strong><u>Reactions,</u></strong><strong><u> </u></strong><strong>Chronic</strong><strong> </strong><strong>Pain</strong><strong> </strong><strong>Trials</strong><strong> </strong><strong>- Pediatrics)</strong></p><p>&nbsp;</p><p><strong>Elderly or Debilitated Patients: </strong>In elderly, cachectic, or debilitated patients, FENTANYL TRANSDERMAL SYSTEM may have altered pharmacokinetics due to poor fat stores, muscle wasting or altered clearance. The clearance of fentanyl may be reduced, and the terminal half-life prolonged (see <strong>DOSAGE AND ADMINISTRATION).</strong></p><p>Data from intravenous studies with fentanyl suggest that elderly patients may have reduced clearance, a prolonged half-life, and they may be more sensitive to the drug than younger patients. In a study conducted with fentanyl transdermal system healthy elderly subjects had fentanyl pharmacokinetics which did not differ significantly from healthy young subjects although peak serum concentrations tended to be lower and mean half-life values were prolonged to approximately 34 hours. Elderly patients should be observed carefully for signs of fentanyl toxicity and the dose reduced if necessary (see <strong>DOSAGE</strong><strong> AND ADMINISTRATION).</strong></p><p><strong>Hepatic Impairment: </strong>In a study conducted with patients with hepatic cirrhosis, the pharmacokinetics of a single 50 &micro;g/hr application of fentanyl transdermal system were assessed. Although Tmax&nbsp;and T&frac12;&nbsp;were not altered, the mean plasma Cmax&nbsp;and AUC values increased by approximately 35% and 73%, respectively, in these patients. Patients with hepatic impairment should be observed carefully for signs of fentanyl toxicity and the dose of FENTANYL TRANSDERMAL SYSTEM reduced if necessary.</p><p><strong>Renal Impairment: </strong>Data obtained from a study administering IV fentanyl in patients undergoing renal transplantation suggest that the clearance of fentanyl may be reduced in this patient population. If patients with renal impairment receive FENTANYL TRANSDERMAL SYSTEM, they should be observed carefully for signs of fentanyl toxicity and the dose should be reduced if necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fentanyl has been administered by the oral, intravenous, intramuscular or subcutaneous routes either acutely or subacutely to rats, mice, guinea pigs, hamsters and cats. Laboratory animals tolerate relatively large doses of fentanyl in comparison to the doses recommended for human use (generally not more than 0.002-0.005 mg/kg).</p><p>&nbsp;</p><p><strong><u>Acute Toxicity</u></strong></p><p>Intravenous LD50&nbsp;determinations showed that the rat and guinea pig, with an LD50&nbsp;in the 2-3 mg/kg range, were the most sensitive species tested; the mouse and dog were more tolerant, having LD50&#39;s in the 11 - 14 mg/kg range. Intramuscular LD50&nbsp;determinations showed that the rat was the most sensitive species tested, having an LD50&nbsp;of 1 mg/kg; the most tolerant species was the hamster with an LD50&nbsp;of 65 mg/kg.</p><p>&nbsp;</p><p><strong><u>Carcinogenicity</u></strong></p><p>In a two-year carcinogenicity study conducted in rats, fentanyl was not associated with an increased incidence of tumors at subcutaneous doses up to 33 &micro;g/kg/day in males or 100 &micro;g/kg/day in females (0.16 and 0.39 times the human daily exposure obtained via the 100 mcg/h patch based on AUC0-24h&nbsp;comparison).</p><p>&nbsp;</p><p><strong><u>Subacute Toxicity </u><u>- Rats</u></strong></p><p>Four weeks of repeated administration of fentanyl by the intramuscular route (0, 0.1 and 0.4 mg/kg/day) and intravenous routes (0, 0.01, 0.02, 0.03, 0.05 and 0.075 mg/kg/day) were without effect on hematologic profile, food consumption, or gross or microscopic examination, with the exception of some local irritation at intramuscular sites. Intramuscular administration was associated with a low mortality incidence; following intravenous administration, mortality was present at 0.03 mg/kg/day and above.</p><p>Oral administration of fentanyl at doses of 5, 10, 20, 40, 80, 160 and 320 mg/kg/day for 14 days resulted in mortality at 10 mg/kg/day and above; survivors were noted to have bloody urine and bloody diarrhea which subsided during the second week of treatment.</p><p>&nbsp;</p><p><strong><u>Subacute Toxicity </u><u>- Dogs</u></strong></p><p>Intramuscular administration of 0, 0.1 and 0.4 mg/kg/day of fentanyl for four weeks did not produce significant effects on hematologic profile, body weight, organ weight, or gross or microscopic examinations. Intravenous administration of 0.1, 0.3 and 1.0 mg/kg/day for four weeks did not produce any mortality or significant gross lesions.</p><p>Physical signs associated with intravenous treatment included slight decrease in body weight, sedation, hypercapnia and decreased food consumption at all dosage levels, and convulsions principally at the high-dosage level. In addition, dogs in the high-dosage group had some pathology of the liver (mild cholestasis and granular cytoplasm in hepatocytes) and kidney (granular casts in collecting tubules or vacuolation) that may have been drug related; however, none of the lesions were considered severe or irreversible.</p><p>&nbsp;</p><p><strong><u>Tissue Irritation Studies</u></strong></p><p>Tissue irritation studies demonstrated that transdermal system fentanyl elicited mild skin irritation and had little or no sensitization potential.</p><p>Studies of rabbits receiving 28 and 90 days of transdermal fentanyl administration showed no differences among the 3 treatment groups (negative control, TT placebo and TT fentanyl) with regard to hematology, blood chemistries or histological evaluations of skin and systemic tissues.</p><p>&nbsp;</p><p><strong><u>Teratology</u></strong></p><p>Adult rats of a Wistar substrain were used in studies to determine the possible teratological effects of fentanyl on dams and their offspring. Three successive generations received fentanyl subcutaneously during the first 21 days of pregnancy, in daily doses of 0.04, 0.08, 0.16 and 0.31 mg/rat. No congenital abnormalities were produced in the experimental groups, but there were dose-related decreases in dam survival, survival <em>in utero </em>and average litter size and weight. A slight delay in delivery time and an increased mortality of the newborn were also observed in rats receiving fentanyl.</p><p>&nbsp;</p><p><strong><u>Mutagenicity</u></strong></p><p>Fentanyl tested negative in the Ames Assay, UDS assay and Mammalian Cell Transformation Assay. Fentanyl did not cause chromosomal aberrations <em>in vitro </em>in human lymphocytes or in Chinese hamster ovary cells in the presence or absence of an exogenous metabolic source.</p><p>In the L5178Y Mouse Lymphoma Assay, fentanyl was nongenotoxic without activation. With activation, fentanyl at concentrations of 37 mcg/mL and higher demonstrated mutation frequencies above control levels; these concentrations are approximately 2,000 times greater than plasma levels observed with a fentanyl transdermal system in clinical use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p><p><strong>Name</strong><strong> </strong><strong>of the excipients(s)</strong></p></td></tr><tr><td><p>Polyisobutene Adhesive (B-12)</p></td></tr><tr><td><p>Polyisobutene Adhesive (B-80)</p></td></tr><tr><td><p>Polybutene (Panalane H-300E)</p></td></tr><tr><td><p>Isopropyl Myristate</p></td></tr><tr><td><p>Octyldodecanol</p></td></tr><tr><td><p>Polyester Backing, 1109</p></td></tr><tr><td><p>Polyester Release Liner, Saint Gobain 8310</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FENTANYL TRANSDERMAL SYSTEM should be stored in sealed pouch below 25&deg;C. Do not refrigerate or freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FENTANYL TRANSDERMAL SYSTEM is comprised of a release liner, a functional layer and a backing. Proceeding from the outer surface towards the surface adhering to the skin, these layers are 1) a backing layer of polyethylene/aluminum/polyester film, 2) an adhesive matrix containing isopropyl myristate, octyldodecanol, polybutene and polyisobutene and the active ingredient, fentanyl and 3) a protective release liner made of polyester. The peelable release liner must be removed before the system can be applied.</p><p>IMPERMEABLE BACKING</p><p>FENTANYL IN PIB ADHESIVE</p><p>MATRIX RELEASE LINER</p><p><img width="138" height="110" alt="" src="data:image/jpeg;base64,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" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Used systems should be folded so that the adhesive side of the system adheres to itself, then flushed down the toilet immediately upon removal (see <strong>SPECIAL HANDLING INSTRUCTIONS).</strong></p><p>FENTANYL TRANSDERMAL SYSTEM should be kept out of the reach of children before and after use.</p><p>Do not cut FENTANYL TRANSDERMAL SYSTEM patches.</p><p>Used systems should be folded so that the adhesive side of the system adheres to itself, then flushed down the toilet immediately upon removal. If the drug adhesive layer accidentally contacts the skin, the area should be washed with clear water. Do not use soap, alcohol, or other solvents, &nbsp;as these may enhance the drug&rsquo;s ability to penetrate the skin. Patients should dispose of any systems remaining from a prescription as soon as they are no longer needed. Unused systems should be removed from their protective pouch, folded so that the adhesive side of the patch adheres to itself, and flushed down the toilet.</p><p>Wash hands with water only, after applying or removing the patch.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>